Mitochondrial disorders : The Essential

3rd quarter 2026



Quarterly literature review
carried out by the AFM-Téléthon documentation department

This literature review, carried out based on queries on PubMed® without claiming to be exhaustive, presents a selection of references to medical-scientific articles concerning the field of mitochondrial diseases.

Summary

ATAXIE DE FRIEDREICH - *FRIEDREICH ATAXIA* 3

ATROPHIE OPTIQUE AUTOSOMIQUE DOMINANTE – *AUTOSOMAL DOMINANT OPTIC ATROPHY (ADOA)* 6

ENCEPHALOPATHIE MYO-NEURO-GASTROINTESTINALE - *MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY (MNGIE)* 7

MALADIE DE CHARCOT-MARIE-TOOTH D'ORIGINE MITOCHONDRIALE – *MITOCHONDRIAL CHARCOT-MARIE-TOOTH DISEASE* 7

MALADIES LIEES AU GENE ACO2 - *ACO2-RELATED DISORDERS* 8

MALADIE LIEE AU GENE GFM1 – GFM1-RELATED DISORDER 8

MALADIES LIEES AU GENE POLG (INCLUS SANDO, SCAE) - *POLG-RELATED DISORDERS (INCLUDED SANDO, SCAE)* 9

MELAS 10

MERFF 14

NEUROPATHIE OPTIQUE HEREDITAIRE DE LEBER - *LEBER HEREDITARY OPTIC NEUROPATHY (LHON)* 14

OPHTALMOPLEGIE EXTERNE PROGRESSIVE – *PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA (PEO)* 17

SYNDROME D'ALPERS-HUTTENLOCHER - *ALPERS-HUTTENLOCHER SYNDROME* 18

SYNDROME DE BARTH – *BARTH SYNDROME* 18

SYNDROME DE KEARNS-SAYRE – *KEARNS-SAYRE SYNDROME* 19

SYNDROME DE LEIGH - *LEIGH SYNDROME* 20

MALADIES MITOCHONDRIALES (AUTRES) – *MITOCHONDRIAL DISORDERS (OTHER)* 22

Ataxie de Friedreich - *Friedreich ataxia*

Aschoff, C. A. M., Silva, T. O., Hasan, A., Migliorini, E., Donis, K. C., Rare Genomes Project Consortium, null, Pellerin, D., Saraiva-Pereira, M. L., Leistner, S., Poswar, F., Giugliani, R., Netto, C. B. O., Ashton-Prolla, P., Saute, J. A. M. et Jardim, L. B. (2026). **The Real Life of Ataxia Patients Without a Vertical Family History: a Twenty-year Experience in South Brazil**. Cerebellum *25*, 128, doi:10.1007/s12311-026-02067-2.

Booth, S., Vallortigara, J., Hurt, C., Greenfield, J., Hunt, B. et Giunti, P. (2026). **Access to specialist ataxia centres in Europe: cross-sectional surveys in the United Kingdom, Italy, and Germany**. Front Health Serv *6*, 1787866, doi:10.3389/frhs.2026.1787866.

Brandon, C. J., Robinson-Thiewes, S., Kaulage, M., Rosikiewicz, W., Cuneo, M. J., Brett, J., Kandola, J., Lang, W. H., Low, J., Mohammed, A., Danda, A., Rider, S., Valentine, M., Ochoada, J., Young, B., Nguyen, T., Kietlinska, S. J., Taylor, A. B., Hoeckendorf, B., Rodrigues, P., Lin, W., Khairy, K., Xu, B., Shelat, A. A., Chen, T., Mittag, T. et Ansari, A. Z. (2026). **BRD4 recruitment into HP1 condensates desilences transcription without erasure of repressive chromatin**. Nat Cell Biol *28*, 1846-1856, doi:10.1038/s41556-026-02044-1.

Brown, H. et Barañano, K. (2026). **Pediatric Ataxia and Emerging Treatments**. Pediatr Neurol *183*, 141-145, doi:10.1016/j.pediatrneurol.2026.07.021.

Cho, H., Sayana, R., Koladiya, A., Colella, P., Cho, S., Jahng, J. W. S., Vasquez, J. J., Arozqueta Basurto, J., Wu, J. C. et Gomez-Ospina, N. (2026). **Myeloid cell replacement induces intercellular mitochondrial transfer and restores metabolism in a mouse model of mitochondrial disease**. Nat Commun *17*, 9829, doi:10.1038/s41467-026-76775-y.

de Gusmao, C. M., Katanaev, V. L., Silveira-Moriyama, L., Pringsheim, T. et Roze, E. (2026). **Novel and Emerging Therapies for Childhood-Onset Movement Disorders**. Mov Disord, doi:10.1002/mds.70495.

Garah, B., Aljabri, H., Aljohani, A., Alnuzha, E., Maihoub, A., Almuzaini, R., Aljohani, L., Alshamani, L. et Alluqmani, M. (2026). **Evolution of Friedreich's Ataxia Management Across Established and Emerging Therapies-Systematic Review and Meta-Analysis**. J Clin Med *15*, 5707, doi:10.3390/jcm15145707.

Gitman, A., Bhandari, N., Castellaro, M., Schadt, K., Cancio, M. et Lynch, D. R. (2026). **Stem Cell Transplantation in Friedreich Ataxia: Cure for Leukemia but No Effect on Neurological Progression**. Ann Clin Transl Neurol *13*, 1733-1735, doi:10.1002/acn3.70455.

Gunsaulus, M. E., Krishnamurthy, R., Alvarado, C., Nandi, D., Cripe, L. H., Waldrop, M. A. et Hayes, E. A. (2026). **Characterizing Friedreich's ataxia cardiomyopathy with serial cardiac magnetic resonance imagings**. Ann Pediatr Cardiol *19*, 364-373, doi:10.4103/apc.apc_22_26.

Hao, Y. et Hao, X. (2026). **Predicting disease progression in progressive cerebellar ataxias: integrating clinical, imaging, fluid, genetic, and digital biomarkers**. Front Neurol *17*, 1921210, doi:10.3389/fneur.2026.1921210.

Karaa, A., Lopez Sanchez, M. I. G., Stuart, C., Bolliger, L., Murray, K., O'Hanlon, M. E., Tseng, B., Yeske, P. et Murray, S. (2026). **2000-2025: Emerging therapies in primary mitochondrial disease: A structured review, horizon scan, and roadmap for the future**. Ther Adv Rare Dis *7*, 26330040261473291, doi:10.1177/26330040261473291.

Kırboğa, K. K. et Küçüksille, E. U. (2026). **Directional information flow in human frataxin defines allosteric pathways connecting the hydrophobic core to the iron-binding ridge**. FEBS J, doi:10.1111/febs.70687.

Lazdovska, K., Baborikina, A., Krutovs, V., Rozevska, M. et Ķēniņa, V. (2026). **Hereditary and Non-hereditary Cerebellar Ataxias in Latvia: Six Years of Experience at the National Reference Centre (ERN-RND Affiliated Partner)**. Cerebellum *25*, 145, doi:10.1007/s12311-026-02084-1.

Lee, C.-L., Chuang, C.-K., Chang, Y.-H., Chiu, H.-C., Tu, Y.-R., Lo, Y.-T., Wu, J.-Y., Huang, H.-Y., Lin, H.-Y. et Lin, S.-P. (2026). **Mitochondrial Quality Control in Inherited Mitochondrial Cardiomyopathy: Convergent Pathobiology and a Testable Therapeutic Framework**. Int J Mol Sci *27*, 8270, doi:10.3390/ijms27188270.

Lynch, D. R., Bidichandani, S. I., Napierala, J. S. et Napierala, M. (2026a). **Friedreich Ataxia: From Genetics to Mechanism to Clinical Features**. Annu Rev Pathol, doi:10.1146/annurev-pathmechdis-032025-035253.

Lynch, D. R., Keita, M., Gunther, K., Park, C., Schadt, K., Mercer-Rosa, L. et Lin, K. Y. (2026b). **Serial assessment of echocardiographic measures in Friedreich ataxia**. Am Heart J Plus *70*, 100869, doi:10.1016/j.ahjo.2026.100869.

Melville, I. Z., Smith, A. H., Coad, G. B., Thorne, P. R., Roxburgh, R. H. et Taylor, R. L. (2026). **Hearing Aid Benefit in Auditory Neuropathy Due to Friedreich Ataxia: A Case Report**. J Speech Lang Hear Res *69*, 5051-5061, doi:10.1044/2026_JSLHR-25-00671.

Mercado-Ayón, E., Coulman, J., Lee, J.-Y., Lancaster, E., Goga, E., Asad, M., Witze, E. et Lynch, D. R. (2026). **Impaired Glur2 palmitoylation in cerebellar Purkinje cells of a Friedreich ataxia mouse model**. Exp Neurol *406*, 115955, doi:10.1016/j.expneurol.2026.115955.

Mundada, A. R., Badikol, A. R. et Mangu, K. (2026). **CRISPR-Cas9-based therapies for Huntington's disease and Friedreich's ataxia: mechanisms, advances, and future perspectives**. Neurogenetics *27*, 49, doi:10.1007/s10048-026-00921-3.

Parisi, V., Barbano, L., Di Renzo, A., Dell'Aquila, C., D'Andrea, M., Castelluzzo, A. M., Colacino, G., Gioiosa, V., Coppola, G., Casali, C. et Ziccardi, L. (2026). **Visual Pathways Involvement in Friedreich's Ataxia Patients Without Macular Impairment**. J Clin Med *15*, 6097, doi:10.3390/jcm15156097.

Pilotto, F., Dall'Agnol, L., Reutenauer, L., Paschaki, M. et Puccio, H. (2026). **Physiologically Regulated Frataxin Gene Replacement Restores Neurological Function in a Mouse Model of Friedreich Ataxia**. Hum Gene Ther 10430342261474315, doi:10.1177/10430342261474315.

Ramchunder, Z., Kalef-Ezra, E., Suleman, S., Edzeamey, F. J., Szunyogh, S., Gittins, O., Castro Mena, N., Wade-Martins, R., Valle, A., Pourzand, C. et Anjomani Virmouni, S. (2026). **Dysregulation of sphingolipid-metabolizing enzymes in Friedreich's ataxia: In vitro and in vivo insights into therapeutic targeting**. iScience *29*, 116479, doi:10.1016/j.isci.2026.116479.

Saha, S., Georgiou-Karistianis, N., Teo, V., Corben, L. A., Szmulewicz, D. J., Strike, L. T., França, M. C., Rezende, T. J. R. et Harding, I. H. (2026). **Multimodal Magnetic Resonance Imaging and Machine Learning Uncovers Distinct Progression Patterns in Friedreich Ataxia**. Mov Disord, doi:10.1002/mds.70551.

Sarwinska, D., Buchholz, M., Iskandar, A., Grobe-Einsler, M., Klockgether, T., Faber, J. et Michalowsky, B. (2026). **Key Interventions in Friedreich's Ataxia and Their Impact on Patient Outcomes: A Systematic Review**. Mov Disord, doi:10.1002/mds.70423.

Tortoriello, S., Rossi, S., Della Valle, I., D'Ambrosi, N. et Cozzolino, M. (2026). **Autophagy at the Crossroads of Protein and RNA Toxicity in Repeat Expansion Cerebellar Ataxias**. Cells *15*, 1411, doi:10.3390/cells15151411.

Tranchant, C. (2026). **Autosomal recessive cerebellar ataxia: What have we learnt in the last 30 years?** Rev Neurol (Paris) S0035-3787(26)00604-1, doi:10.1016/j.neurol.2026.09.002.

Turki, E., Jullian, E., Delamotte, P., Filipe, A., Tixier-Cardoso, L., Middendorp, S., Martin, E. et Monnier, V. (2026). **Limiting intestinal iron absorption rescues glial defects and extends lifespan in a Drosophila model of Friedreich's ataxia**. Neurobiol Dis *228*, 107550, doi:10.1016/j.nbd.2026.107550.

Wainman, E., Guy, T. O., Hernandez, N., Faust, P. L. et Louis, E. D. (2026). **Purkinje Cell Loss and Changes in Basket Cell Morphology in Essential Tremor and Other Cerebellar Degenerative Diseases: A Postmortem Study of 332 Brains**. Cerebellum *25*, 133, doi:10.1007/s12311-026-02075-2.

Wang, H., Marutani, E., Zazzeron, L., Menard, M., Volpicelli-Daley, L., Ichinose, F. et Mootha, V. K. (2026). *A second-generation "hypoxia in a pill" rescues neurodegenerative phenotypes across distinct mouse models*, doi:10.64898/2026.06.30.734089.

Yang, W., Thompson, B., Miellet, S., Maddock, M., Napierala, M., Dottori, M. et Kwa, F. A. A. (2026). **Unlocking Sulforaphane's Potential in Friedreich Ataxia: Further Evidence from Preclinical Investigations Using Induced Pluripotent Stem Cell-Derived Sensory Neurons**. Antioxid Redox Signal *45*, 561-580, doi:10.1177/15230864261470377.

Atrophie optique autosomique dominante – *Autosomal dominant optic atrophy (ADOA)*

Bouzidi, A., Amati-Bonneau, P., Desquiret-Dumas, V., Beaulieu, C., Guichet, A., Bris, C., Bocquet, B., Dieu, X., Reynier, P., Mirebeau-Prunier, D., Houdayer, C., Planes, M., Odent, S., Meunier, I., Bonneau, D., Charif, M., Lenaers, G. et Zanlonghi, X. (2026). **Phenotypic Variations in a Large Family with Dominant Optic Atrophy Related to a Novel OPA1 Deletion**. Ophthalmol Sci *6*, 101286, doi:10.1016/j.xops.2026.101286.

Khalilimeybodi, A., Qiao, L., Leung, A., McCulloch, A. D., Schenk, S. et Rangamani, P. (2026). **Systems modelling of mitochondrial dynamics in different exercise regimes**. J Physiol *604*, 6369-6390, doi:10.1113/JP290424.

Küçük, H. C., Koçak, N., Özizmirliler, D., Doğruya, S. et Devebacak, A. (2026). **Genotype-Phenotype Correlation in Dominant Optic Atrophy due to OPA1 c.3011T>C (p.Leu1004Pro): A Family-Based Case Series**. J Curr Ophthalmol *38*, 79-86, doi:10.4103/joco.joco_4_26.

Liang, H., Chen, Z., Huang, S., Wei, H., Xu, J. et Hu, S. (2026). **Domain-Specific Genotype-Phenotype Correlations in DNM1L Disorders: Insights Into Mutation Hotspots and Clinical Severity**. FASEB J *40*, e72087, doi:10.1096/fj.202502759RR.

Encéphalopathie myo-neuro-gastrointestinale - *Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)*

Cengiz, N. (2026). **Trigeminal neuralgia expands the clinical spectrum of MNGIE: a 5-year follow-up**. Neurol Sci *47*, 734, doi:10.1007/s10072-026-09330-8.

Maladie de Charcot-Marie-Tooth d'origine mitochondriale – *Mitochondrial Charcot-Marie-Tooth disease*

Ali, Z., Jameel, M., Klar, J., Suleman, M., Batool, U., Yousaf, H., Ali, F., Fatima, A., Baig, S. M., Dahl, N., Toft, M., Abdullah, U. et Iqbal, Z. (2026). **Genetic basis of Charcot-Marie-Tooth disease in Pakistani consanguineous families**. Front Neurol *17*, 1920139, doi:10.3389/fneur.2026.1920139.

Arredondo, N. T., DaSilva, M. A., Brown, M. R., Gavrielatos, M., Helsel, S. M., Googins, M. R., Freyberg, Z., Koes, D. R., Kiselyov, K. I. et VanDemark, A. P. (2026). **Conformational plasticity in GDAP1's GST-like domain enables thapsic acid recognition**. J Biol Chem *302*, 113378, doi:10.1016/j.jbc.2026.113378.

Carrera Garcia, L., Estévez-Arias, B., Nascimento, A., Expósito, J., Cerezo, S., Lotz-Esquivel, S., Zschaeck, I., Lujan, A., Gatnau, C., Tizzano, E., Natera De Benito, D. et Ortez, C. (2026). **[Clinical pattern and evolution of Charcot-Marie-Tooth disease in pediatrics]**. Medicina (B Aires) *86 Suppl 3*, 1-6.

Fortanier, E., Bonello-Palot, N., Verschueren, A., Kouton, L., Grapperon, A.-M., Salort-Campana, E., Corazza, G., de Bovis, V. M., du Closel, L. B., Delmont, E. et Attarian, S. (2026). **Late-onset CMT neuropathy in the NGS era: a 10-year retrospective study**. J Neurol *273*, 624, doi:10.1007/s00415-026-14154-9.

Jestice, L. H., Butler, L., Lea, R. A., Adamson, K. I., Van Lent, J., Johnson, S. L., Weedon, H., D'Silva, E., Gelezauskaite, G., Asselbergh, B., Brown, E., Laing, O., Price, C. J., Stavish, D., Tsakiridis, A., Collins, M. O., Timmerman, V., De Vos, K. J., Twelvetrees, A. E., Grierson, A. J. et Barbaric, I. (2026). **HDAC6 inhibition alleviates mitochondrial trafficking in models of Charcot-Marie-Tooth disease type 2A**. JCI Insight *11*, e200106, doi:10.1172/jci.insight.200106.

Kölbel, H., Hentschel, A., Preuße, C., Tiet, M., Dohrn, M. F., Muhmann, D., van den Ameele, J., Chen, L., Schara-Schmidt, U., Weis, J., Horvath, R., Mensch, A. et Roos, A. (2026). **When muscles matter in SORD neuropathy**. J Neuropathol Exp Neurol nlag057, doi:10.1093/jnen/nlag057.

Rebelo, A. P., Lutz, K., Grider, T., Zaidman, C. M., Shy, M. E. et Zuchner, S. (2026). **Biallelic SCO2 Variants Presenting as Motor-Predominant Axonal Neuropathy With Complex IV Deficiency**. J Peripher Nerv Syst *31*, e70150, doi:10.1111/jns.70150.

Sharma, S., Nagappa, M., Narayanappa, G., Sharma, K. K., Bhaskarapillai, B., Chickabasaviah, Y. T. et Taly, A. B. (2026). **Mitochondrial abnormalities in Charcot-Marie-Tooth disease: insights from a family harbouring a novel GDAP1 variant**. Neuromuscul Disord *67*, 107401, doi:10.1016/j.nmd.2026.107401.

Weigele, J., Franco, A. et Dorn, G. W. (2026). **Neuromuscular Dysfunction and Charcot-Marie-Tooth Disease Reversal in Mfn2 T105M Knock-In Rats**. Int J Mol Sci *27*, 7376, doi:10.3390/ijms27167376.

Yang, J., Park, H.-M. et Lee, Y.-B. (2026). **Late-Onset Rapidly Progressive Spastic Paraplegia with Extensive White Matter Abnormalities Associated with an MFN2 Variant**. NeuroSci *7*, 82, doi:10.3390/neurosci7040082.

Zanfardino, P., Amati, A., Cox, S., Agrimi, G., Doccini, S., Fernández-Silva, P., Tullo, A., Rosati, J., Santorelli, F. M. et Petruzzella, V. (2026). **Mitochondrial dysfunction, metabolic quiescence and premature senescence in CMT4B3 fibroblasts**. Hum Mol Genet *35*, ddag080, doi:10.1093/hmg/ddag080.

Zhang, B., Zhang, M., Liu, K., Zhao, C., Zhang, J., Liu, Z., Fan, Y., Gu, R.-X., Lin, L., Fu, C. et Zhu, J. (2026). **Mechanistic basis for calmodulin-dependent allosteric activation of the neuropathy-associated formin INF2**. Cell Rep *45*, 117750, doi:10.1016/j.celrep.2026.117750.

Maladies liées au gène ACO2 - *ACO2-related disorders*

Pas de résultat ce trimestre / No results

Maladie liée au gène GFM1 – GFM1-related disorder

Pas de résultat ce trimestre / No results

Maladies liées au gène POLG (inclus SANDO, SCAE) - *POLG-related disorders (included SANDO, SCAE)*

Bermejo-Moriñigo, A., Martín-Jiménez, P., González-Méndez, V., Bermejo-Guerrero, L., Ochoa, L. E., Martín-Arriscado, C., Alcalá-Galiano, A., Casado-Pérez, C., Navarro-Riquelme, M., Garrido-Moraga, R., González Quintana, A., Blázquez, A. et Domínguez-González, C. (2026). **Quantitative Muscle MRI Fat Fraction as a Biomarker of Disease Severity in Mitochondrial Myopathies**. J Cachexia Sarcopenia Muscle *17*, e70380, doi:10.1002/jcsm.70380.

Brañas Casas, R., Risato, G., Zuppardo, A., Viscomi, C., Argenton, F., Doimo, M., Facchinello, N. et Tiso, N. (2026). **Correction: Model organisms in POLG-related disorders: insights from yeast to multicellular systems**. Cell Death Dis *17*, 765, doi:10.1038/s41419-026-09022-3.

Bueno, M. V., Delgado, R. Z. R., Ortega, K. et Franco, J. B. (2026). **When Surgical Intervention Becomes a Risk: Severe Drug-Induced Gingival Overgrowth and Clinical Decision-Making in Alpers-Huttenlocher Syndrome**. Spec Care Dentist *46*, e70241, doi:10.1111/scd.70241.

Chen, A., Yangzom, T., Sullivan, G. J. et Liang, K. X. (2026). **Impaired NADH-linked mitochondrial respiration disrupts ventral midbrain neuronal programs in POLG disease**. J Transl Med *24*, 988, doi:10.1186/s12967-026-08706-w.

Dalwadi, S., Engelhardt, N. M., Muraresku, C. C., Keith, K., Valverde, K. D., Nathanson, K. L. et Falk, M. J. (2026). **Cancer prevalence in primary mitochondrial disease patients and their families**. Ther Adv Rare Dis *7*, 26330040261471914, doi:10.1177/26330040261471914.

Duy, P. Q., Dong, W., Bukhbinder, A. et Pier, D. B. (2026). **A Heterozygous Pathogenic Variant in POLG Associated With Isolated Neuropathic Pain and Rhabdomyolysis**. Pediatr Neurol *184*, 9-10, doi:10.1016/j.pediatrneurol.2026.07.033.

Lim, A. Z., Moe, A.-M., Stefanetti, R. J. et Ng, Y. S. (2026). **Advances in Primary Mitochondrial Diseases: Diagnosis, Natural History Studies and Clinical Trials**. Genes (Basel) *17*, 850, doi:10.3390/genes17080850.

Melo, C. F., de Vasconcelos, L. T. et Evangelista, L. A. B. (2026). **Progressive Axonal Neuropathy and Cerebellar Ataxia Associated with Homozygous Pathogenic POLG Mutation in a Patient of African Descent from Northern Minas Gerais/Jequitinhonha Valley, Brazil: A Case Report and Epidemiological Implications**. Tremor Other Hyperkinet Mov (N Y) *16*, 52, doi:10.5334/tohm.1238.

Myers, K. A., Buhas, D. et Waters, P. J. (2026). **Author response to Commentary on « Long-term safety and efficacy of deoxycytidine/deoxythymidine in treatment of POLG-related disorders »**. Neurotherapeutics *23*, e01072, doi:10.1016/j.neurot.2026.e01072.

Rožmarić, G., Hero, M., Papić, E., Grozdanić, N. et Vuletić, V. (2026). **Late-onset PSP/FTD-like atypical parkinsonism as a novel phenotype of POLG-related disease: a case report**. Acta Neurol Belg, doi:10.1007/s13760-026-03145-2.

Solares, I., Alegre, E., Colina, I., Gavira, J. J., Alvarez de Sierra, B., Llorente-Gonzalez, S. et Gonzalez, Á. (2026). **When rare diseases do not appear as a single entity**. Adv Lab Med *7*, 234-237, doi:10.1515/almed-2025-0193.

Ueda, N. K., Mimaki, M., Wang, Z., Mizuno, Y., Namai, Y., Nishino, I. et Goto, Y.-I. (2026). **Twelve Japanese patients with POLG-related disorders: Population-specific genetic differences of POLG variants in Japan and Europe**. Brain Dev *48*, 104590, doi:10.1016/j.braindev.2026.104590.

MELAS

Adams, J. A., Ko, T., Sultan, L. R., Sarna, T., McGinn, D., Uryash, A., Lopez, J. R., Nadkarni, V., Xiao, R., Falk, M. J., Ischiropoulos, H. et Zolkipli-Cunningham, Z. (2026). **Endothelial-mitochondrial coupling in mitochondrial disease: A systematic review and quantitative synthesis of vascular, biochemical, and oxidative bioenergetic dysfunction**. Ther Adv Rare Dis *7*, 26330040261480132, doi:10.1177/26330040261480132.

Almannai, M., Duong, J., El-Hattab, A. W., Ali, M., Bauri, D., Hawk, N., Soler-Alfonso, C., Delay, L., Chu, Z. D., Liu, N., Gijavanekar, C., Elsea, S. H., Kralik, S. F., Lee, S. et Scaglia, F. (2026). **L-citrulline treatment of nitric oxide deficiency in MELAS a phase I dose-finding and safety study**. Mol Genet Metab *149*, 110209, doi:10.1016/j.ymgme.2026.110209.

Avdonina, E. D., Kutsev, S. I. et Shestopalov, A. V. (2026). **The Role of Autophagy in the Pathogenesis of Mitochondrial Diseases**. Cells *15*, 1371, doi:10.3390/cells15151371.

Azzimonti, M., Padelli, S., Ronchi, D., Sacco, S., Comi, G. P. et Corti, S. (2026). **Headache in mitochondrial diseases: From migraine to stroke-like episodes**. Headache, doi:10.1111/head.70180.

Boggan, R. M., Michalettou, T.-D., Ng, Y. S., Franklin, I. G., Cortés, L. T., Alston, C. L., Blakely, E. L., Büchner, B., Bugiardini, E., Colclough, K., Feeney, C., Hanna, M. G., Hattersley, A. T., Klopstock, T., Kornblum, C., Mancuso, M., Patel, K. A., Pitceathly, R. D. S., Pizzamiglio, C., Prokisch, H., Schäfer, J., Schaefer, A. M., Shepherd, M. H., Thaele, A., Thomas, R. H., Turnbull, D. M., Woodward, C. E., McFarland, R., Taylor, R. W., Cordell, H. J. et Pickett, S. J. (2026). **Identification of Nuclear Genetic Loci Linked to Clinical Features of the m.3243A>G Mitochondrial DNA Variant**. Neurol Genet *12*, e200411, doi:10.1212/NXG.0000000000200411.

Burattini, M., Pisano, A., Pignataro, M. G., d'Amati, G., Pinelli, S., Hoang, M. L., Lo Muzio, F. P. et Miragoli, M. (2026). **Kinematic-calcium loops unravel impaired excitation-contraction coupling in MELAS-affected cardioids**. J Physiol, doi:10.1113/JP290473.

Chan, Z., Chan, K. L., Lam, C. K., Law, W. P., Pak, W. L. W., Wong, Y. H. et Wong, S. S. H. (2026). **Peritoneal Dialysis for End-Stage Kidney Disease due to Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS): A Case Report**. Nephrology (Carlton) *31*, e70283, doi:10.1111/nep.70283.

Chang, S. M., Park, H. H., Park, J. H., Na, J.-H., Lee, H., Lee, Y.-M. et Yoo, J. (2026). **Glioblastoma in a Patient With MELAS Syndrome: A Case Report**. Brain Tumor Res Treat *14*, 159-163, doi:10.14791/btrt.2026.0015.

Chu, K.-Y. (2026). **Mitochondrial DNA A3243G variant-associated MELAS: Recent advances in clinical trials, therapeutic interventions, and disease-modifying strategies**. Intractable Rare Dis Res *15*, 219-231, doi:10.5582/irdr.2026.01026.

Finsterer, J. (2026a). **Hyperintensity on Diffusion-Weighted Imaging in a MELAS Patient Does Not Necessarily Mean Cytotoxic Edema**. J Child Neurol *41*, 1384-1385, doi:10.1177/08830738261463070.

Finsterer, J. (2026b). **Pyloric Stenosis as a Manifestation of MELAS Is Unlikely**. JSLS *30*, e2026.00083, doi:10.4293/JSLS.2026.00083.

Finsterer, J. (2026c). **The Proof of Variant m.3243A>G does not Necessarily Mean MELAS**. Endocr Metab Immune Disord Drug Targets *26*, e18715303487861, doi:10.2174/0118715303487861260523100425.

Kanai, M., Tsuru, H., Onuki, T., Nukaga, S., Baba, S., Tsukada, M., Abe, T., Numano, F., Murayama, K. et Saitoh, A. (2026). **Pulmonary Hypertension with a High-Output Hemodynamic Profile in a Child with MELAS: A Case Report**. Intern Med, doi:10.2169/internalmedicine.7614-26.

Kawakubo, H., Ryu, S., Imaizumi, Y., Suzuki, D., Nakashima, S., Goto, K., Kamada, T., Okamoto, A., Kobayashi, Y., Takano, Y., Takeda, Y., Ito, R., Eto, K. et Yamaguchi, K. (2026). **A case of severe enteritis following CapeOX therapy in a postoperative rectal cancer patient with m.3243A>G-associated mitochondrial disease**. Int Cancer Conf J *15*, 568-574, doi:10.1007/s13691-026-00901-2.

Lee, F. S., Lee, C. W., Lee, C. H. et Hunley, V. (2026). **Rare Pyloric Stenosis in Mitochondrial Disease Treated with Hand-Assisted Laparoscopic Pyloromyotomy**. CRSLS *13*, e2026.00033, doi:10.4293/CRSLS.2026.00033.

Lu, Y.-S. et Lin, K.-L. (2026). **Reply to Comment on: « Based on a Single Case, Cardiopulmonary Training Cannot Be Recommended as Therapy for Hemiparesis in MELAS With Ischemic Stroke »**. Kaohsiung J Med Sci e70295, doi:10.1002/kjm2.70295.

Mathot, A. et Maraite, F. (2026). **[Acute anterior ischemic optic neuropathy in the context of mitochondrial disease]**. Rev Med Liege *81*, 536-543.

Mehri, S. et Finsterer, J. (2026). **Based on a Single Case, Cardiopulmonary Training Cannot Be Recommended as Therapy for Hemiparesis in MELAS With Ischemic Stroke**. Kaohsiung J Med Sci e70294, doi:10.1002/kjm2.70294.

Merdžo, I., Jurišić, D., Ćavar, I. et Striber, N. (2026). **Visual disturbances in a 12-year-old male patient with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome**. Taiwan J Ophthalmol *16*, 342-346, doi:10.4103/tjo.TJO-D-23-00123.

O'Connell, P. (2026). *A human cytokine response atlas to reconstruct underlying gene regulatory networks*, doi:10.64898/2026.07.27.740961.

Rajavoor Muniswamy, J. K., Stewart, M., Eggenberger, E. et Muthusamy, K. (2026). **Vitelliform retinal lesions: Uncommon adult-onset presentation of the common mitochondrial MELAS variant**. Mol Genet Metab *149*, 110245, doi:10.1016/j.ymgme.2026.110245.

Saura, P., Badolato, S., Gangdal, A., Beghiah, A. et Kaila, V. R. I. (2026). **Disease-mutations perturb proton transfer reactions in respiratory complex I**. Biochim Biophys Acta Bioenerg *1867*, 149602, doi:10.1016/j.bbabio.2026.149602.

Shen, L., Lott, M. T., Mccormick, E. M., Muraresku, C. C., Keller, K., Wallace, D. C., Zolkipli-Cunningham, Z., Rahman, S., Falk, M. J. et Gai, X. (2026). **MSeqDR PMD-VR: An Expert-Curated Virtual Registry of 11,000 Mitochondrial Disease Cases Established Through Literature Mining and Generative AI Augmentation**. Genes (Basel) *17*, 757, doi:10.3390/genes17070757.

Shinozaki, T., Sumiyoshi, H., Ueshima, D., Onaka, J. et Tajima, K. (2026). **Phenotypic overlap masking MELAS in Turner syndrome: a diagnostic challenge**. Eur Heart J Case Rep *10*, ytag578, doi:10.1093/ehjcr/ytag578.

Tang, H., Liu, J., Cai, X., Leng, F., Hu, J., Zhao, Y., Wang, Z. et Yu, L. (2026). **Analysis of acute stroke-like lesions in MELAS: Distribution, potential boundaries and spreading pattern**. Neuroimage Rep *6*, 100365, doi:10.1016/j.ynirp.2026.100365.

Tian, Y., Chen, T., Liu, J., Wang, J. et Zhang, L. (2026). **Lamotrigine-induced Stevens-Johnson syndrome in the setting of mitochondrial encephalomyopathy: A case report**. Ther Adv Neurol Disord *19*, 17562864261474798, doi:10.1177/17562864261474798.

Tsai, Y.-L., Cheng, K.-Y., Lu, Y.-S. et Lin, K.-L. (2026). **Cardiopulmonary Exercise Testing (CPET) Guided Sub-Anaerobic Threshold Rehabilitation in MELAS Syndrome: A Case Report**. Kaohsiung J Med Sci e70266, doi:10.1002/kjm2.70266.

Yan, C., Zhang, S., Zhang, P., Zhang, J., Liu, Yang, Zhou, H., Jiang, H., Zhang, Z., Guo, J., Zhang, W., Liang, F., Zou, Z., Chen, J., Chen, W., Lu, X., Yu, L., Xie, W., Pi, C., Zhao, H., Liu, Yusha, Ma, J., Gao, S., Yu, S. et Wu, S. (2026). **Mitochondrial migraine: A multicenter study based on mitochondrial diseases presenting as encephalopathy and/or myopathy**. Headache, doi:10.1111/head.70225.

Yap, L. E. et Bruce, S. S. (2026). **Headache Attributed to Genetic Vasculopathies**. Curr Pain Headache Rep *30*, 111, doi:10.1007/s11916-026-01536-x.

Zarrouk, S. et Finsterer, J. (2026). **The diagnosis MELAS requires extensive work-up and defined criteria**. Epileptic Disord, doi:10.1002/epd2.70258.

Zhang, L., Lin, J., Li, F., Jia, Y., Li, J. et Wang, X. (2026). **Late-onset mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes with chronic intestinal pseudo-obstruction: a case-based review**. Front Mol Biosci *13*, 1857438, doi:10.3389/fmolb.2026.1857438.

MERFF

Avdonina, E. D., Kutsev, S. I. et Shestopalov, A. V. (2026). **The Role of Autophagy in the Pathogenesis of Mitochondrial Diseases**. Cells *15*, 1371, doi:10.3390/cells15151371.

Dy Closas, A. M. F., Yu, J. R. T., Saranza, G. et Fugoso, L. (2026). **Cerebellar ataxia in the Philippines: a scoping review of reported cases and practical approach**. J Neural Transm (Vienna), doi:10.1007/s00702-026-03192-2.

Kang, Y., Kim, B.-E., Kim, J. H. et Park, S. H. (2026). **Anesthetic management of patient with myoclonic epilepsy with ragged red fibers, a mitochondrial disease - A case report**. Anesth Pain Med (Seoul), doi:10.17085/apm.26610.

Puertas-Frías, G., Saucedo-Rodríguez, M. J., Čunátová, K., Alán, L., Hrbáč, P., Knězů, M., Koníčková, S., Schimmer, J., Krakovková, M., Vrbacký, M., Čajka, T., Kuda, O., Fernández-Vizarra, E., Zeviani, M., Hansíková, H., Honzík, T., Houštěk, J., Pecina, P., Mráček, T. et Pecinová, A. (2026). **Polyunsaturated fatty acid sequestration protects against mitochondrial dysfunction-induced ferroptosis**. EMBO Rep *27*, 5382-5406, doi:10.1038/s44319-026-00898-y.

Neuropathie optique héréditaire de Leber - *Leber hereditary optic neuropathy (LHON)*

Ai, C., Li, H., Wu, J., Zhou, T., Wang, J., Pan, S.-H., Yu, J., Wallace, D. C. et Guan, M.-X. (2026). **Allotopic expression of ND6 restores vision in a mitochondrial disease model**. JCI Insight *11*, e209108, doi:10.1172/jci.insight.209108.

Altares, V. J., Castro Rebollo, M. et González Martín-Moro, J. (2026). **Late-Onset Leber Hereditary Optic Neuropathy: A Report of a Case and Review of the Literature**. Cureus *18*, e110551, doi:10.7759/cureus.110551.

Ambika, S. et Srilekha, S. (2026). **Systematic review of Leber's hereditary optic neuropathy - Clinical diagnosis, genetics overview and current concepts of treatment**. Indian J Ophthalmol *74*, 1151-1161, doi:10.4103/IJO.IJO_1696_25.

Battista, M., Carbonelli, M., Brotto, L., Amore, G., Coutinho, C. P., Romagnoli, M., Galzignato, A., Nucci, P., Caporali, L., Cascavilla, M. L., Fiorini, C., La Morgia, C., Bandello, F., Carelli, V. et Barboni, P. (2026). **Late-onset Leber Hereditary Optic Neuropathy: disease triggers and prognostic factors in a large Italian cohort**. Ophthalmology S0161-6420(26)00586-5, doi:10.1016/j.ophtha.2026.08.017.

Coutinho, C. P., Zanchetta, F., Carbonelli, M., Battista, M., Galzignato, A., La Morgia, C., Amore, G., Romagnoli, M., Brotto, L., Nucci, P., Parisi, V., Cascavilla, M. L., Caporali, L., Bandello, F., Sadun, A. A., Carelli, V., Fioresi, R. et Barboni, P. (2026). **Archetypal Visual Field Analysis of Patients With Chronic Leber Hereditary Optic Neuropathy in Relation to Visual Recovery**. Invest Ophthalmol Vis Sci *67*, 8, doi:10.1167/iovs.67.8.8.

Dzwilewski, K., Krygier, M., Szymarek, J., Zawadzka, M., Stodolska-Koberda, U. et Mazurkiewicz-Bełdzińska, M. (2026). **When LHON Mimics Demyelination: Area Postrema Syndrome in Biallelic DNAJC30 Variants**. J Clin Med *15*, 5289, doi:10.3390/jcm15135289.

Guan, W., Li, W., Li, Z., Peng, L., Shao, S. et Zhang, J. (2026). **Progressive mitochondrial and autophagic dysfunction during RGC development driven by a LHON-associated mitochondrial tRNAThr mutation**. Cell Signal *148*, 112778, doi:10.1016/j.cellsig.2026.112778.

Hedström, J., Nilsson, M., Fagerström, S., Engvall, M., Williams, P. A. et Venkataraman, A. P. (2026). **Functional and structural analysis in relation to age at onset of Leber hereditary optic neuropathy: a Swedish cohort**. Eye (Lond), doi:10.1038/s41433-026-04866-7.

Ji, Y., Meng, F., Gao, Y., Nie, Z., He, Y., Zhang, J., Li, Y., Zhang, M., Wang, J., Zhang, Y., Wei, S., Mo, J. Q. et Guan, M.-X. (2026). **Genetic architecture and inheritance patterns of Leber hereditary optic neuropathy among 419 Chinese pedigrees carrying the ND4 11778G>A mutation**. J Genet Genomics S1673-8527(26)00272-9, doi:10.1016/j.jgg.2026.08.007.

Karaa, A., Lopez Sanchez, M. I. G., Stuart, C., Bolliger, L., Murray, K., O'Hanlon, M. E., Tseng, B., Yeske, P. et Murray, S. (2026). **2000-2025: Emerging therapies in primary mitochondrial disease: A structured review, horizon scan, and roadmap for the future**. Ther Adv Rare Dis *7*, 26330040261473291, doi:10.1177/26330040261473291.

Kolotova, A., Shestopalov, A. et Kutsev, S. (2026). **The Role of Apoptosis and Ferroptosis in Primary Mitochondrial Diseases: Mechanisms and Pathogenesis**. Int J Mol Sci *27*, 5931, doi:10.3390/ijms27135931.

Lee, J.-J., Hsiao, Y.-T., Huang, H.-M., Ke, M.-C., Tsao, S.-T., Huang, Y.-S. et Lin, T.-K. (2026). **Inhibition of STING protects the neuroretina in an Ndufs4 knockout mouse model of mitochondrial complex 1 deficiency**. Exp Eye Res *273*, 111238, doi:10.1016/j.exer.2026.111238.

Mathot, A. et Maraite, F. (2026). **[Acute anterior ischemic optic neuropathy in the context of mitochondrial disease]**. Rev Med Liege *81*, 536-543.

Orenburkina, O. I., Frolov, M. A., Babushkin, A. E., Vorobyeva, I. V., Frolov, A. M. et Koshelev, D. I. (2026). **[Leber's hereditary optic nerve atrophy]**. Vestn Oftalmol *142*, 105-111, doi:10.17116/oftalma2026142041105.

Sandali, A., Nikolaidou, A., Gianni, T., Tsoukala, Z., Tsinopoulos, I. et Lamprogiannis, L. (2026). **Gene therapy clinical trials for inherited eye diseases: The pediatric perspective**. Eur J Ophthalmol 11206721261478166, doi:10.1177/11206721261478166.

Saura, P., Badolato, S., Gangdal, A., Beghiah, A. et Kaila, V. R. I. (2026). **Disease-mutations perturb proton transfer reactions in respiratory complex I**. Biochim Biophys Acta Bioenerg *1867*, 149602, doi:10.1016/j.bbabio.2026.149602.

Solares, I., Alegre, E., Colina, I., Gavira, J. J., Alvarez de Sierra, B., Llorente-Gonzalez, S. et Gonzalez, Á. (2026). **When rare diseases do not appear as a single entity**. Adv Lab Med *7*, 234-237, doi:10.1515/almed-2025-0193.

Takai, Y., Yamagami, A., Inoue, K., Yasumoto, R. et Ishikawa, H. (2026a). **Acute-phase characteristics of RNFL thickness in older patients with Leber hereditary optic neuropathy: a single-center retrospective OCT study**. Int Ophthalmol *46*, 330, doi:10.1007/s10792-026-04202-8.

Takai, Y., Yamagami, A. et Ishikawa, H. (2026b). **Systemic comorbidities before and after onset in Leber hereditary optic neuropathy: a descriptive study**. Ophthalmic Genet 1-4, doi:10.1080/13816810.2026.2717328.

Tran, A. et Micieli, J. (2026). **Novel Variants in Mitochondrial Ribosomal RNA Genes MT-RNR1 and MT-RNR2 Identified in Hereditary Optic Neuropathy Initially Presenting as Normal Tension Glaucoma: A Case Report**. Case Rep Ophthalmol *17*, 853-859, doi:10.1159/000553606.

Ophtalmoplégie externe progressive – *Progressive external ophthalmoplegia (PEO)*

Aldosary, M., AlQudairy, H., Alshalan, N., Al-Muhaizea, M. A., Alobeid, E., AlBakheet, A., Khouj, E., Alharbi, A. M., Alenazi, W., Omar, H. R., Alhamdoosh, M., Alsuwaidan, A., Alhindi, H., Alfares, A., Alazami, A. M., Arold, S. T., Colak, D., Taylor, R. W. et Kaya, N. (2026). **A Novel SLC25A4 Variant Causing Mitochondrial Dysfunction, Myopathy and Cardiomyopathy: A Functional and Molecular Characterization**. Int J Mol Sci *27*, 6978, doi:10.3390/ijms27156978.

Bermejo-Moriñigo, A., Martín-Jiménez, P., González-Méndez, V., Bermejo-Guerrero, L., Ochoa, L. E., Martín-Arriscado, C., Alcalá-Galiano, A., Casado-Pérez, C., Navarro-Riquelme, M., Garrido-Moraga, R., González Quintana, A., Blázquez, A. et Domínguez-González, C. (2026). **Quantitative Muscle MRI Fat Fraction as a Biomarker of Disease Severity in Mitochondrial Myopathies**. J Cachexia Sarcopenia Muscle *17*, e70380, doi:10.1002/jcsm.70380.

Finsterer, J. (2026). **Autosomal Dominant TWNK Mutations More Likely Manifest with Multisystem Disease than Isolated External Ophthalmoplegia**. Intern Med, doi:10.2169/internalmedicine.8109-26.

Starosta, R. T., Friederich, M. W., Preston, G., Walson, L., Yin, J. H., Lang, S., Tadros, H. J., Wang, Y., Mizerik, E., Mirsky, D., Hock, D. H., Stroud, D. A., Sanchez Russo, R., Scaglia, F., Morava, E. et Van Hove, J. L. K. (2026). **Delineation and Phenotypic Expansion of TOP3A-Related Mitochondrial Disease in Childhood**. Am J Med Genet A, doi:10.1002/ajmg.a.70248.

Ueda, N. K., Mimaki, M., Wang, Z., Mizuno, Y., Namai, Y., Nishino, I. et Goto, Y.-I. (2026). **Twelve Japanese patients with POLG-related disorders: Population-specific genetic differences of POLG variants in Japan and Europe**. Brain Dev *48*, 104590, doi:10.1016/j.braindev.2026.104590.

Yoshida, C., Kubota, A., Kawamoto, N., Takahashi, K., Yano, S., Komaki, S., Maeda, M., Naruse, H., Matsukawa, T., Hamada, M., Satake, W. et Toda, T. (2026). **Response to: Autosomal Dominant TWNK Mutations more likely Manifest with Multisystem Disease than Isolated External Ophthalmoplegia**. Intern Med, doi:10.2169/internalmedicine.8159-26.

Syndrome d'Alpers-Huttenlocher - *Alpers-Huttenlocher syndrome*

Bueno, M. V., Delgado, R. Z. R., Ortega, K. et Franco, J. B. (2026). **When Surgical Intervention Becomes a Risk: Severe Drug-Induced Gingival Overgrowth and Clinical Decision-Making in Alpers-Huttenlocher Syndrome**. Spec Care Dentist *46*, e70241, doi:10.1111/scd.70241.

Syndrome de Barth – *Barth syndrome*

Amedro, P., Andrianoely, M., Gohier, P., Leroux, J., Aladjidi, N., Lagorce, S., Daccord, M., Audie, M., Botte, A., Nubret, K., Richard, P., Roche, S., Lamireau, D., Tetard, C., Trimouille, A., Desir, A., Mesli, S., Donadieu, J. et Gotchac, J. (2026). **Elamipretide in pediatric Barth syndrome: from heart failure to school return**. Orphanet J Rare Dis *21*, 340, doi:10.1186/s13023-026-04487-z.

Arita, K., Kido, T., Taira, M., Watanabe, T., Narita, J., Ishida, H., Ishii, R., Ueno, T. et Miyagawa, S. (2026). **Successful bridge to heart transplantation in a pediatric patient with biventricular heart failure associated with Barth syndrome: a case report**. J Artif Organs *29*, 60, doi:10.1007/s10047-026-01587-2.

Karaa, A., Lopez Sanchez, M. I. G., Stuart, C., Bolliger, L., Murray, K., O'Hanlon, M. E., Tseng, B., Yeske, P. et Murray, S. (2026). **2000-2025: Emerging therapies in primary mitochondrial disease: A structured review, horizon scan, and roadmap for the future**. Ther Adv Rare Dis *7*, 26330040261473291, doi:10.1177/26330040261473291.

Lee, C.-L., Chuang, C.-K., Chang, Y.-H., Chiu, H.-C., Tu, Y.-R., Lo, Y.-T., Wu, J.-Y., Huang, H.-Y., Lin, H.-Y. et Lin, S.-P. (2026). **Mitochondrial Quality Control in Inherited Mitochondrial Cardiomyopathy: Convergent Pathobiology and a Testable Therapeutic Framework**. Int J Mol Sci *27*, 8270, doi:10.3390/ijms27188270.

Petit, P. X. (2026). **Cardiolipin as a Signaling Hub: Evolutionary Conservation and Programmable Platforms Coupling Mitochondrial Stress to Cell Fate**. Int J Mol Sci *27*, 6868, doi:10.3390/ijms27156868.

Ragozzino, J. R. M., Siqueira, A. W., Miura, N. et Azeka, E. (2026). **Barth Syndrome and Referral to Heart Transplantation: Single-Center Experience and Literature Review**. Transplant Proc *58*, 1353-1355, doi:10.1016/j.transproceed.2026.07.013.

Ramim, A., Ralph-Epps, T., Vo, L., Jang, H., Liyanage, J. S. S., Lowran, K. et Greenberg, M. L. (2026). **Loss of TAFAZZIN leads to perturbation of amino acid metabolism and reduction of collagen synthesis**, doi:10.64898/2026.07.19.739395.

Tentler, K., Snider, P. L., Matias, C., Brault, J. J. et Conway, S. J. (2026). **Diaphragmatic Mitochondrial Myopathy in a Patient-Derived Mouse Model of Barth Syndrome**. J Dev Biol *14*, 40, doi:10.3390/jdb14030040.

Villatore, A., Ehle, E. A. et Chelko, S. P. (2026). **Elamipretide: a mitochondria-targeting drug for Barth syndrome**. Trends Pharmacol Sci *47*, 1053-1054, doi:10.1016/j.tips.2026.06.011.

Syndrome de Kearns-Sayre – *Kearns-Sayre syndrome*

Astavans, A. et Barth, A. S. (2026). **From Ophthalmoplegia to Multilevel Atrioventricular Block: Timing Cardiac Device Therapy in Kearns-Sayre Syndrome**. JACC Case Rep *31*, 108241, doi:10.1016/j.jaccas.2026.108241.

Avdonina, E. D., Kutsev, S. I. et Shestopalov, A. V. (2026). **The Role of Autophagy in the Pathogenesis of Mitochondrial Diseases**. Cells *15*, 1371, doi:10.3390/cells15151371.

Rivas, A. C., Falk, V. et Juergens, L. (2026). **CMV-Associated Worsening of Neurological Symptoms in Kearns-Sayre Syndrome After Heart Transplantation: A Case Report**. Transpl Infect Dis *28*, e70268, doi:10.1111/tid.70268.

Sarapultseva, M. et Sarapultsev, A. (2026). **Dental Management of a Child With Mitochondrial DNA Deletion Syndrome (Kearns-Sayre Syndrome): A Case Report**. Spec Care Dentist *46*, e70269, doi:10.1111/scd.70269.

Valls-Roca, L., Vilaseca-Capel, A., Cantó-Santos, J., Tobías, E., Andújar-Sánchez, F., Farré-Tarrats, L., Tort, F., Rentero, C., Enrich, C., López, V., Tejedor, J. R., Esteve-Codina, A., de Arenas, C. N., Moreno-Lozano, P. J., Milisenda, J. C., O'Callaghan, M., García-Silva, T., Morales-Conejo, M., Fraga, M. F., Artuch, R., Martín, M. Á., Cuezva, J. M., Matas, A., Garrabou, G. et Guitart-Mampel, M. (2026). **Patient-Derived Fibroblasts as a Clinically Relevant Model of Kearns-Sayre Syndrome**. Ann Neurol, doi:10.1002/ana.78351.

Syndrome de Leigh - *Leigh syndrome*

Alvi, J. R., Wasim, A., Ahdi, S. G., Sultan, T., Zia-Ur-Rehman, M., Al-Thihli, K., Al Murshedi, F. et Al Futaisi, A. (2026). **Pediatric stroke in inborn errors of metabolism: clinical characteristics, neuroimaging features, and short-term outcomes**. Front Neurol *17*, 1889684, doi:10.3389/fneur.2026.1889684.

Awad, E. K., Waskow, E., Tunuguntla, H., Spinner, J., Tadros, H. J., Emrick, L. T., Calame, D. G. et Scaglia, F. (2026). **COX14 Variants Are Associated With Mitochondrial Complex IV Deficiency Nuclear Type 10 (MC4DN10)**. Am J Med Genet A, doi:10.1002/ajmg.a.70260.

Bérat, C.-M., Barcia, G., Gaignard, P., Assouline, Z., De La Cruz, E., François-Heude, M.-C., Roubertie, A., Cances, C., Dufour, L., Alison, M., Patat, O., Trimouille, A., Saadi, S. A.-E.-M., Rötig, A., Hully, M., Rouzier, C., Desguerre, I., Boddaert, N. et Schiff, M. (2026). **TTC19-related mitochondrial disease: A characteristic neuroimaging signature?** Mol Genet Metab *149*, 110220, doi:10.1016/j.ymgme.2026.110220.

Brister, D., Zarate-Mendez, M., Hathazi, D. et Horvath, R. (2026). **The role of impaired mitochondrial function in neurological manifestations of mitochondrial diseases**. Mamm Genome *37*, 108, doi:10.1007/s00335-026-10278-5.

Ferrera, G., Invernizzi, F., Spagnolo, M., Lamantea, E., Moroni, I. et Ardissone, A. (2026). **Riboflavin therapy in complex I deficiency: Two new cases of leukoencephalopathy and a systematic literature review**. J Neurol Sci *489*, 126095, doi:10.1016/j.jns.2026.126095.

Gouiza, I., Bouzidi, A., Hechmi, M., Charif, M., Zioudi, A., Kheriji, N., Boudabous, H., Zribi, M., Khatrouch, S., Kebaili, R., Ben Youssef-Turki, I., Trabelsi, M., Abdelmoula, S., Kraoua, I., Ben Chehida, A., Kefi, R. et Lenaers, G. (2026). **Integrated exome and mitochondrial genome sequencing reveals the genetic landscape of primary mitochondrial diseases: findings from a large Tunisian cohort**. Mitochondrion *91*, 102195, doi:10.1016/j.mito.2026.102195.

Greenspon, N. H., Higgins, N. et Nieb, J. M. (2026). **Navigating the Mitochondrial Maze: A Case Report of Emergent Cesarean Delivery After Labor Induction in a Patient With Leigh Syndrome**. A A Pract *20*, e02247, doi:10.1213/XAA.0000000000002247.

Hanaford, A. R., Olkhova, E. A., Liao, R., Ching, A., Huang, A., Hsieh, E. S., Watanabe, K., Chen, Y., Wichman, M., Hwang, N., James, K., Mulholland, M., Truong, V., Coulson, H., Gibbins, K., Cairns, O., Dimitriou, A., Kayser, E.-B., Johnson, B. M., Surojit, S., Kalia, V. et Johnson, S. C. (2026). **MyD88 deficiency modestly attenuates disease in a Leigh syndrome mouse model while enrofloxacin accelerates disease**. J Neuropathol Exp Neurol nlag102, doi:10.1093/jnen/nlag102.

Johnson, B. M. et Johnson, S. C. (2026). **Perianesthetic Complications in Genetic Mitochondrial Disease: A Review of Case Reports**. Paediatr Anaesth *36*, 1217-1230, doi:10.1002/pan.70257.

Lee, J.-J., Hsiao, Y.-T., Huang, H.-M., Ke, M.-C., Tsao, S.-T., Huang, Y.-S. et Lin, T.-K. (2026). **Inhibition of STING protects the neuroretina in an Ndufs4 knockout mouse model of mitochondrial complex 1 deficiency**. Exp Eye Res *273*, 111238, doi:10.1016/j.exer.2026.111238.

MacMullen, L. E., Stanley, K. D., Christodoulou, J., Cohen, B. H., Demczko, M., Goldstein, A. C., Haas, R., Koenig, M. K., Poblete, M., Rice, A., Rossman, I., Ruiz, C., Russo, S. N., Thorburn, D. R., Uebergang, E., Yang, J. H., Zolkipli-Cunningham, Z., Falk, M. J., et Leigh Syndrome Roadmap Project Natural History Study Consortium (2026). **Interim analysis of an international multi-site prospective natural history study evaluating the clinical presentation and progression of Leigh syndrome spectrum disorders**. Ther Adv Rare Dis *7*, 26330040261476231, doi:10.1177/26330040261476231.

Narang, I., Au, C. T. et Chen, M. L. (2026). **Central Sleep Apnea and Hypoventilation Disorders in Children**. Sleep Med Clin *21*, 377-396, doi:10.1016/j.jsmc.2026.05.004.

Nogueira, C. et Vilarinho, L. (2026). **Can early diagnosis of Leigh syndrome impact prognosis?** Expert Rev Neurother 1-4, doi:10.1080/14737175.2026.2725112.

Ohtake, A., Abe, Y., Murayama, K., Shiraishi, H., Osaka, H., Kumada, S., Ito, T., Kondo, H., Hamada, Y., Suzuki-Ajihara, S., Arao, M., Ueda, Y., Nagai, K., Ichimoto, K., Matsunaga, A., Kashii, H., Nakajima, Y., Nakagawa, H., Kurose, S., Fukuda, K., Takahashi, K., Yamauchi, M. et Nakajima, M. (2026). **A phase III double-blind, placebo-controlled, randomized withdrawal trial of 5-aminolevulinic acid hydrochloride with sodium ferrous citrate for efficacy and safety in patients diagnosed as Leigh syndrome**. PLoS One *21*, e0332283, doi:10.1371/journal.pone.0332283.

Saura, P., Badolato, S., Gangdal, A., Beghiah, A. et Kaila, V. R. I. (2026). **Disease-mutations perturb proton transfer reactions in respiratory complex I**. Biochim Biophys Acta Bioenerg *1867*, 149602, doi:10.1016/j.bbabio.2026.149602.

Shen, L., Lott, M. T., Mccormick, E. M., Muraresku, C. C., Keller, K., Wallace, D. C., Zolkipli-Cunningham, Z., Rahman, S., Falk, M. J. et Gai, X. (2026). **MSeqDR PMD-VR: An Expert-Curated Virtual Registry of 11,000 Mitochondrial Disease Cases Established Through Literature Mining and Generative AI Augmentation**. Genes (Basel) *17*, 757, doi:10.3390/genes17070757.

Starosta, R. T., Friederich, M. W., Preston, G., Walson, L., Yin, J. H., Lang, S., Tadros, H. J., Wang, Y., Mizerik, E., Mirsky, D., Hock, D. H., Stroud, D. A., Sanchez Russo, R., Scaglia, F., Morava, E. et Van Hove, J. L. K. (2026). **Delineation and Phenotypic Expansion of TOP3A-Related Mitochondrial Disease in Childhood**. Am J Med Genet A, doi:10.1002/ajmg.a.70248.

Tofilo, M., Volodyaev, I., Tretiakov, E., Kokorina, O., Avdeichik, S., Smirnova, A., Grechenko, E., Filimonova, A., Sudarikova, N., Kirillova, A. et Mazunin, I. (2026). **Concordant mtDNA heteroplasmy between trophectoderm and inner cell mass supports blastocyst-stage PGT-mt for m.14487T>C**. J Assist Reprod Genet, doi:10.1007/s10815-026-04012-y.

Wang, H., Marutani, E., Zazzeron, L., Menard, M., Volpicelli-Daley, L., Ichinose, F. et Mootha, V. K. (2026). *A second-generation "hypoxia in a pill" rescues neurodegenerative phenotypes across distinct mouse models*, doi:10.64898/2026.06.30.734089.

Maladies mitochondriales (autres) – *Mitochondrial disorders (other)*

Abu-Amero, K. K. (2026). **Mitochondrial Genetic Diseases and Ophthalmic Manifestations: Molecular Pathophysiology, Genetics, and Clinical Management**. Int J Mol Sci *27*, 6128, doi:10.3390/ijms27146128.

Adams, J. A., Ko, T., Sultan, L. R., Sarna, T., McGinn, D., Uryash, A., Lopez, J. R., Nadkarni, V., Xiao, R., Falk, M. J., Ischiropoulos, H. et Zolkipli-Cunningham, Z. (2026). **Endothelial-mitochondrial coupling in mitochondrial disease: A systematic review and quantitative synthesis of vascular, biochemical, and oxidative bioenergetic dysfunction**. Ther Adv Rare Dis *7*, 26330040261480132, doi:10.1177/26330040261480132.

Ahola, S. (2026). **Mitochondria setting the stage for ferroptosis**. Trends Endocrinol Metab S1043-2760(26)00150-5, doi:10.1016/j.tem.2026.06.006.

Ai, C., Li, H., Wu, J., Zhou, T., Wang, J., Pan, S.-H., Yu, J., Wallace, D. C. et Guan, M.-X. (2026). **Allotopic expression of ND6 restores vision in a mitochondrial disease model**. JCI Insight *11*, e209108, doi:10.1172/jci.insight.209108.

Akyüzlüer Güneş, M. S., Koç Yekedüz, M., Köse, E., Sürücü Kara, İ. et Eminoğlu, F. T. (2026). **Prescribing patterns of vitamin and cofactor therapies in genetically confirmed primary mitochondrial diseases**. Mol Genet Metab *149*, 110247, doi:10.1016/j.ymgme.2026.110247.

Aldosary, M., AlQudairy, H., Alshalan, N., Al-Muhaizea, M. A., Alobeid, E., AlBakheet, A., Khouj, E., Alharbi, A. M., Alenazi, W., Omar, H. R., Alhamdoosh, M., Alsuwaidan, A., Alhindi, H., Alfares, A., Alazami, A. M., Arold, S. T., Colak, D., Taylor, R. W. et Kaya, N. (2026). **A Novel SLC25A4 Variant Causing Mitochondrial Dysfunction, Myopathy and Cardiomyopathy: A Functional and Molecular Characterization**. Int J Mol Sci *27*, 6978, doi:10.3390/ijms27156978.

Alsharhan, H., Alostad, W., Ali, A. A., Ebrahim, M. A., Mohammed, H. A. F., Alahmad, A., Alhashemi, H., Hassan, W. M., Alhaj, A. E. M. S., Alsafi, R. M. et Albash, B. (2026). **A Homozygous Founder ELAC2 Variant in Kuwaiti Infants With Fatal Cardiomyopathy and Refractory Severe Lactic Acidosis: A Retrospective Review of the Clinical, Cardiological and Molecular Findings**. Mol Genet Genomic Med *14*, e70274, doi:10.1002/mgg3.70274.

Altıntaş, M., Yıldırım, M., Bektaş, Ö., Eyduran, E., Ergin, B., Karabulut, H. G., Köse, E., Eminoğlu, F. T., Kendirli, T. et Teber, S. (2026). **A Case of Paroxysmal Exercise-Induced Dyskinesia Expands the Phenotypic spectrum of NAXE-Related Encephalopathy**. J Child Neurol 8830738261467625, doi:10.1177/08830738261467625.

Alvi, J. R., Wasim, A., Ahdi, S. G., Sultan, T., Zia-Ur-Rehman, M., Al-Thihli, K., Al Murshedi, F. et Al Futaisi, A. (2026). **Pediatric stroke in inborn errors of metabolism: clinical characteristics, neuroimaging features, and short-term outcomes**. Front Neurol *17*, 1889684, doi:10.3389/fneur.2026.1889684.

Aoyama, Y., Grafstein, J., Houston, P., Friederich, M. W., Van Hove, R. A., Michel, C. R., Reisdorph, R., Van Hove, J., Gahl, W., Adams, D. R., Wolfe, L. et Macnamara, E. F. (2026). **Unusual Variants in NDUFAF6-Associated Mitochondrial Disease**. Rare *5*, 100129, doi:10.1016/j.rare.2026.100129.

Arranz Chamorro, I., Blanco-Schweizer, P., Ruiz Pesini, E., Busto Busto, M., Ticona Espinoza, T. et Rodríguez Jiménez, J. (2026). **An adult case of acute encephalopathy associated with general anaesthesia and the m.11232T>C MT-ND4 variant**. Rev Esp Anestesiol Reanim (Engl Ed) 502103, doi:10.1016/j.redare.2026.502103.

Avdonina, E. D., Kutsev, S. I. et Shestopalov, A. V. (2026). **The Role of Autophagy in the Pathogenesis of Mitochondrial Diseases**. Cells *15*, 1371, doi:10.3390/cells15151371.

Awad, E. K., Waskow, E., Tunuguntla, H., Spinner, J., Tadros, H. J., Emrick, L. T., Calame, D. G. et Scaglia, F. (2026). **COX14 Variants Are Associated With Mitochondrial Complex IV Deficiency Nuclear Type 10 (MC4DN10)**. Am J Med Genet A, doi:10.1002/ajmg.a.70260.

Azzimonti, M., Padelli, S., Ronchi, D., Sacco, S., Comi, G. P. et Corti, S. (2026). **Headache in mitochondrial diseases: From migraine to stroke-like episodes**. Headache, doi:10.1111/head.70180.

Bakis, H., Trimouille, A., Schwarz, M., Combe, C., Boudhabhay, I., Martin-Négrier, M.-L. et Rigothier, C. (2026). **Primary Mitochondrial-Disorders-Associated Nephropathy in Adulthood**. Kidney Int Rep *11*, 106999, doi:10.1016/j.ekir.2026.106999.

Basan, H., Gökalp, S., Özsaydı Aktaşoğlu, E., Akar, H. T., Şeker, R. et Kılıç, M. (2026). **Hypercobalaminemia in children: clinical characteristics and ınherited metabolic diagnoses in a tertiary-center cohort**. Eur J Pediatr *185*, 696, doi:10.1007/s00431-026-07360-0.

Becker, A., Eichmann, T. O., Vasiliev, V., Mey, K. A., Petzsch, P., Rossi, A., Distelmaier, F. et Anand, R. (2026). **MIC13-linked cristae disruption causes metabolic failure and early fibrotic remodelling in mitochondrial liver disease**. Cell Death Dis *17*, 801, doi:10.1038/s41419-026-09283-y.

Bérat, C.-M., Barcia, G., Gaignard, P., Assouline, Z., De La Cruz, E., François-Heude, M.-C., Roubertie, A., Cances, C., Dufour, L., Alison, M., Patat, O., Trimouille, A., Saadi, S. A.-E.-M., Rötig, A., Hully, M., Rouzier, C., Desguerre, I., Boddaert, N. et Schiff, M. (2026). **TTC19-related mitochondrial disease: A characteristic neuroimaging signature?** Mol Genet Metab *149*, 110220, doi:10.1016/j.ymgme.2026.110220.

Bermejo-Moriñigo, A., Martín-Jiménez, P., González-Méndez, V., Bermejo-Guerrero, L., Ochoa, L. E., Martín-Arriscado, C., Alcalá-Galiano, A., Casado-Pérez, C., Navarro-Riquelme, M., Garrido-Moraga, R., González Quintana, A., Blázquez, A. et Domínguez-González, C. (2026). **Quantitative Muscle MRI Fat Fraction as a Biomarker of Disease Severity in Mitochondrial Myopathies**. J Cachexia Sarcopenia Muscle *17*, e70380, doi:10.1002/jcsm.70380.

Blagov, A. V., Orekhov, N. A., Rozhkova, U., Antonov, S., Utkina, A. et Orekhov, A. N. (2026). **The pivotal role of mitochondrial disorders in cancer development with a special focus on mitochondria-mediated apoptosis**. Cell Mol Biol (Noisy-le-grand) *72*, 41-55, doi:10.14715/cmb/2026.72.4.6.

Brister, D., Zarate-Mendez, M., Hathazi, D. et Horvath, R. (2026). **The role of impaired mitochondrial function in neurological manifestations of mitochondrial diseases**. Mamm Genome *37*, 108, doi:10.1007/s00335-026-10278-5.

Chen, K., Wang, M., Kam, C., Wang, Z., Zhang, Q. et Chen, S. (2026). **A Molecular Engineering Strategy to Fine-Tune Phototoxicity of AIE Probes for Super-Resolution Imaging of Mitochondrial Cristae Dynamics**. Adv Sci (Weinh) e24281, doi:10.1002/advs.202524281.

Cho, H., Sayana, R., Koladiya, A., Colella, P., Cho, S., Jahng, J. W. S., Vasquez, J. J., Arozqueta Basurto, J., Wu, J. C. et Gomez-Ospina, N. (2026). **Myeloid cell replacement induces intercellular mitochondrial transfer and restores metabolism in a mouse model of mitochondrial disease**. Nat Commun *17*, 9829, doi:10.1038/s41467-026-76775-y.

Colacurci, D., Sarno, L., Fiore, E., Raimondi, F., Martinelli, N., Sirico, A., Di Carlo, C., Bifulco, G., Guida, M. et Maruotti, G. M. (2026). **Genomic Sequencing in Neonatal Encephalopathy and Suspected Hypoxic-Ischaemic Encephalopathy: A Systematic Review**. Genes (Basel) *17*, 862, doi:10.3390/genes17080862.

Couto, M., Soares, M. D., Coelho, P., Roque, R. et Brum, M. (2026). **Identification of a novel likely pathogenic MT-TS2 variant in a patient with mitochondrial myopathy, retinitis pigmentosa and sensorineural hearing loss**. Neuromuscul Disord *67*, 107395, doi:10.1016/j.nmd.2026.107395.

Dalwadi, S., Engelhardt, N. M., Muraresku, C. C., Keith, K., Valverde, K. D., Nathanson, K. L. et Falk, M. J. (2026). **Cancer prevalence in primary mitochondrial disease patients and their families**. Ther Adv Rare Dis *7*, 26330040261471914, doi:10.1177/26330040261471914.

de Bruijn, D. G. J., Gusinac, A., Ederveen, T. H. A., Le, N. D., Kulkarni, P., Meijer, R. I., Janssen, M. C. H. et Zweers, H. E. E. (2026). **Gut microbiota alterations in individuals with mitochondrial disease caused by the m.3243A >G mutation**. Mol Genet Metab *149*, 110208, doi:10.1016/j.ymgme.2026.110208.

Del Giudice, L., Guida, M., Aletta, M. R. et Pontieri, P. (2026). **Targeting mitochondrial ribosomal proteins: a functional and translational framework for neurodegenerative disease research**. Front Neurol *17*, 1882474, doi:10.3389/fneur.2026.1882474.

de Medeiros, G. N., Berton, G. G., Visentini, L. M., Alves E Gomes, A. D., Costa, C. P. A., de Almeida Paiva, L. et Fagundes, T. P. (2026). **Late gadolinium enhancement in mitochondrial myopathy: a systematic review and meta-analysis of cardiovascular magnetic resonance studies**. Clin Radiol *102*, 107454, doi:10.1016/j.crad.2026.107454.

de Melo, R. S. E. S., Mitsunaga Júnior, J. K., da Silva, A. M. S., Souza, B. W., Santos, J. M., Andrade, P. V., Oliveira, A. S. B., Sobreira, C. F. da R., Vainzof, M. et da Silva, H. C. A. (2026). **Lightning Strikes Twice in the Same Place: Mitochondrial Myopathy and Malignant Hyperthermia-A Case Report**. Case Rep Neurol Med *2026*, 5802797, doi:10.1155/crnm/5802797.

Domínguez-González, C. (2026). **Management of patients with thymidine kinase 2 deficiency: where are we now?** Expert Opin Pharmacother *27*, 1379-1383, doi:10.1080/14656566.2026.2720613.

Dua, N., Ma, B., Oviedo, S., Rahmani, H., Boyd, T., Park, D., Wiseman, R. L. et Grotjahn, D. A. (2026). *ATAD3A structurally links mtDNA replication and mitochondrial fission*, doi:10.64898/2026.06.23.733767.

Elsharkawi, I., Preston, G., Kozicz, T. et Morava, E. (2026). **Phosphodiesterase-5 inhibition as an off-label therapy in mitochondrial disease**. Mol Genet Metab *149*, 110261, doi:10.1016/j.ymgme.2026.110261.

Faisal, A., Waqas, H., Masood, H., Butt, A., Rahman, S., Hameed, M. S., Zaidi, S. R. H., Iqbal, A. et Naveed, M. U. (2026). **Pearson syndrome: expanding the clinical spectrum of a mitochondrial cytopathy-a case report**. J Med Case Rep *20*, 390, doi:10.1186/s13256-026-06288-1.

Falahee, B., Apovian, C. M. et Istfan, N. (2026). **Incretin-Based Therapies: A Testable Hypothesis Linking Incretin Signaling, Mitochondrial Redox, and OXPHOS Efficiency**. Obesity (Silver Spring), doi:10.1002/oby.70294.

Fathi, M., Karimzadeh, P., Ahmadabadi, F., Ali, D. N., Jafari, N., Tangestani, R., Salehpour, S., Moosavian, T., Ghafouri-Fard, S. et Miryounesi, M. (2026). **Analysis of whole-exome sequencing data from nearly 10,000 Iranian individuals: identification of recessive mitochondrial disease variants and proposal of a population-specific carrier screening panel**. Hum Genomics *20*, 139, doi:10.1186/s40246-026-01011-z.

Fearn, C., Poulton, J., Fratter, C., Oliva, C., Griguer, C., Baldock, R. A., Robson, S. C. et McGeehan, R. E. (2026). **« NanoDel »: identification of large-scale mitochondrial DNA deletions using long-read sequencing**. Bioinformatics *42*, btag684, doi:10.1093/bioinformatics/btag684.

Ferrera, G., Invernizzi, F., Spagnolo, M., Lamantea, E., Moroni, I. et Ardissone, A. (2026). **Riboflavin therapy in complex I deficiency: Two new cases of leukoencephalopathy and a systematic literature review**. J Neurol Sci *489*, 126095, doi:10.1016/j.jns.2026.126095.

Fraser, B. J., Gower, B., Stanesby, O., Magnussen, C. G., Cadenas-Sanchez, C., Chaput, J.-P., Manyanga, T., McGrath, R., Merucci, K., Myers, J., Ortega, F. B., Singh, B., Prince, S. A., Lang, J. J. et Tomkinson, G. R. (2026). **Diagnostic and Prognostic Accuracy of Cardiorespiratory Fitness for Detecting Cardiovascular Risk and Mitochondrial Disorders: An Overview of Systematic Reviews with Meta-Analyses**. Sports Med, doi:10.1007/s40279-026-02503-7.

Geminiani, M., Trezza, A., Visibelli, A., Finetti, R., Mastroeni, P., Roncaglia, B., Spiga, O. et Santucci, A. (2026). **Clinical proteomics in inborn errors of metabolism: from biomarker discovery to implementation**. Expert Rev Proteomics *23*, 209-222, doi:10.1080/14789450.2026.2709148.

Goode, J. L. M., Sturm, G. et Picard, M. (2026). **The Energetic Cost of Adrenergic Signaling in Primary Human Fibroblasts**, doi:10.64898/2026.07.09.737569.

Gouiza, I., Bouzidi, A., Hechmi, M., Charif, M., Zioudi, A., Kheriji, N., Boudabous, H., Zribi, M., Khatrouch, S., Kebaili, R., Ben Youssef-Turki, I., Trabelsi, M., Abdelmoula, S., Kraoua, I., Ben Chehida, A., Kefi, R. et Lenaers, G. (2026). **Integrated exome and mitochondrial genome sequencing reveals the genetic landscape of primary mitochondrial diseases: findings from a large Tunisian cohort**. Mitochondrion *91*, 102195, doi:10.1016/j.mito.2026.102195.

Gowda, N. et Harish, S. (2026). **Splice-site variants in neurology: from molecular mechanisms to clinical interpretation - a focused review**. Neurogenetics *27*, 75, doi:10.1007/s10048-026-00947-7.

Gowda, V. K., Reddy, V.-S., Namratha, P. et Srinivasan, V. M. (2026). **Striatal Variant of POLR3A: Report of Two Indian Cases**. Neurol India *74*, 642-645, doi:10.4103/neurol-india.Neurol-India-D-25-00386.

Hahl, O. et Martikainen, M. H. (2026). **Acute and Chronic Pancreatitis in Mitochondrial Disease: A Systematic Review**. JIMD Rep *67*, e70125, doi:10.1002/jmd2.70125.

Hamad, K. H., Braim, S. A., Hamad, D. Q., Hamad, S. A., Mohammed, K. K., Kareem, H. O., Hasan, K. M., Mohammed, B. A., Mustafa, A. M. et Kakamad, F. H. (2026). **MICOS13-Related Combined Oxidative Phosphorylation Deficiency 37: A Case Report and Systematic Review of the Literature**. Fetal Pediatr Pathol 1-15, doi:10.1080/15513815.2026.2726271.

Harris, K. E., Lascaratos, G. et Chau, K.-Y. (2026). **Mitochondrial Complex V Dysfunction in Neurodegeneration: Secondary Bystander or Primary Driver?** Brain Sci *16*, 890, doi:10.3390/brainsci16080890.

Hida, M., Suda, K., Fujimoto, T., Goto, H., Watayo, H., Tsunoda, Y., Shimizu, M., Iwakami, T., Nakano, S., Suzuki, M., Zhang, J., Piao, C., Miyake, Y., Shibuya, S., Toma, M., Yanai, T., Urao, M., Okazaki, T., Shoji, H., Yatamaka, A. et Miyano, G. (2026). **Serum growth differentiation factor 15: A novel biomarker for diagnostic and prognostic prediction in biliary atresia**. J Pediatr Surg 163415, doi:10.1016/j.jpedsurg.2026.163415.

Hou, J.-Y., Chou, I.-J., Kuo, C.-Y. et Lin, K.-L. (2026). **Expanding the epilepsy spectrum in primary coenzyme Q10 deficiency with COQ4 variants - Case series and literature review**. Seizure *143*, 31-38, doi:10.1016/j.seizure.2026.09.020.

Iness, A. N., Walimbe, A. S., Strouphauer, E. R., Hirano, M., Iglesias, A. D., Emmanuele, V., Griffin, C. C., Kaplan, S. L., Gomes, W. A., Moeller, K. K., Kralik, S. F. et Scaglia, F. (2026). **Immune Modulatory Therapy for Severe Dengue Hemorrhagic Fever in a Patient With Mitochondrial Complex I Deficiency: A Case Report**. Am J Med Genet A, doi:10.1002/ajmg.a.70258.

Isermann, L. et Trifunovic, A. (2026). **Mitochondrial CLPP in Health and Disease: Mechanisms, Therapeutic Duality and Emerging Opportunities**. J Inherit Metab Dis *49*, e70247, doi:10.1002/jimd.70247.

Järvinen, O. et Martikainen, M. H. (2026). **Drug safety in patients with mitochondrial disease: an observational cohort study**. Neurol Sci *47*, 683, doi:10.1007/s10072-026-09298-5.

Jayan, A. S., Nataraj, P., Gangadharan, A. K., Thomas, O., Mangat, R., Raghavan, C. T., Gopala, S., Sundaram, S. et Urulangodi, M. (2026). **Coenzyme Q10 supplementation restores mitochondrial respiration in patients with primary CoQ10 deficiency caused by novel COQ2 and COQ4 variants**. Metab Brain Dis *41*, 211, doi:10.1007/s11011-026-01983-w.

Jia, M., Wu, Q., Zou, J. et Jin, D. (2026). **A young male with kidney damage from genetic mitochondrial disease: case report and literature review**. BMC Nephrol *27*, 504, doi:10.1186/s12882-026-05238-9.

Johnson, B. M. et Johnson, S. C. (2026). **Perianesthetic Complications in Genetic Mitochondrial Disease: A Review of Case Reports**. Paediatr Anaesth *36*, 1217-1230, doi:10.1002/pan.70257.

Karaa, A., Hareendran, A., Waller, K., Yeske, P., Morrison, A., Ross, M. et Balcells, C. (2026a). **Patients' lived experience of thymidine kinase 2 deficiency: the online survey-based assessment of TK2d patient perspectives study**. Ther Adv Rare Dis *7*, 26330040261469197, doi:10.1177/26330040261469197.

Karaa, A., Lopez Sanchez, M. I. G., Stuart, C., Bolliger, L., Murray, K., O'Hanlon, M. E., Tseng, B., Yeske, P. et Murray, S. (2026b). **2000-2025: Emerging therapies in primary mitochondrial disease: A structured review, horizon scan, and roadmap for the future**. Ther Adv Rare Dis *7*, 26330040261473291, doi:10.1177/26330040261473291.

Kattner, A. A. (2026). **More than just numbers: the expanding burden of non-communicable diseases**. Biomed J *49*, 101020, doi:10.1016/j.bj.2026.101020.

Keegan, A., Çetin, Ö., Chilcott, E. M., Diaz, J. A., Eaton, S., Waddington, S. N., Counsell, J. R., Rahman, S. et Karda, R. (2026). **Next generation AAV-F capsid gene therapy rescues disease pathology in a model of pyruvate dehydrogenase complex deficiency**. Mol Ther Adv *34*, 201781, doi:10.1016/j.omta.2026.201781.

Keith, K., Peng, M., Remes, C., Miranda, V., Wachowski, N., Kose, M., Dharaskar, S., Haroon, S., Velasco, A. B., Sivaramakrishnan, P., Iadarola, D., Dugar, S. et Falk, M. J. (2026). *Targeted modulation of IGFBP5/IGF1, THPO, and P38 MAPK signaling are potent therapeutic strategies generalizable for mitochondrial respiratory chain disease and osteosarcoma*, doi:10.64898/2026.07.20.739625.

Kline, B. L., Compton, A. G., Frazier, A. E., Pachernegg, S., Sinclair, A. H., Ayers, K. L. et Tucker, E. J. (2026). **The role of mitochondrial dysfunction and genetics in female infertility and premature ovarian insufficiency**. Hum Reprod Update dmag022, doi:10.1093/humupd/dmag022.

Kolotova, A., Shestopalov, A. et Kutsev, S. (2026). **The Role of Apoptosis and Ferroptosis in Primary Mitochondrial Diseases: Mechanisms and Pathogenesis**. Int J Mol Sci *27*, 5931, doi:10.3390/ijms27135931.

Kornienko, J., Müller, L. H., Nickel, A., Kohlhaas, M., Börmel, M., Alfonso-Gonzalez, C., Oorschot, V. M. J., Fungate, M., Lewey, S., Kees, J., Müller, J., Lindenhofer, D., Fenzl, K., Schraft, L., Clauder-Münster, S., Konrad, L., Haberkant, P., Montoya, F. D. M., Dauksaite, V., Gotthardt, M., van den Hoogenhof, M. M. G., Maack, C. et Steinmetz, L. M. (2026). **Dysregulated Ribonucleoprotein Granules Impair Mitochondrial Function in RBM20-Related Dilated Cardiomyopathy**. Circulation, doi:10.1161/CIRCULATIONAHA.125.077061.

Koskiniatis, J. A. et Martikainen, M. H. (2026). **Karnofsky performance scale and modified Rankin scale as indicators of functional capacity in patients with mitochondrial disease**. Neurol Sci *47*, 629, doi:10.1007/s10072-026-09212-z.

Lakshmi, P., Chalipat, S., Kunchepu, M. et Mane, S. (2026). **Novel Homozygous Mitochondrial Calcium Uptake Protein 1 Variant (c.38T>C, p.Leu13Pro) in a 7-year-old**

Girl with Congenital Ptosis and Proximal Myopathy: Expanding the Phenotypic Spectrum. Ann Afr Med, doi:10.4103/aam.aam_493_26.

Lambert, L., Rovšnik, U., Moretton, A., Johansson, K., Săcultanu, M., Chéron, M., Porcan, A., Macao, B., van den Wildenberg, S., Zhu, X., Falkenberg, M. et Farge, G. (2026). **SLIRP differentially modulates RNA binding of pathogenic LRPPRC variants**. NAR Mol Med *3*, ugag040, doi:10.1093/narmme/ugag040.

Lando, C., Khawajazada, T., Storgaard, J. H., Poulsen, N. S., Vissing, J. et Løkken, N. (2026). **Plasma Lactate Response to a 12-Min Walk Test Is a Poor Diagnostic Biomarker for Mitochondrial Myopathy**. JIMD Rep *67*, e70112, doi:10.1002/jmd2.70112.

Larson, A., Goettemoeller, J., Goettemoeller, K., Goettemoeller, L., Goldstein, A., Huggan, N., Karaa, A., Leahey, M., Scaglia, F., Yeske, P., Zolkipli-Cunningham, Z. et Hirano, M. (2026). **Progress and perspectives in primary mitochondrial myopathy: Highlights from the 2025 mitochondrial medicine masterclass with a focus on TK2 deficiency**. Ther Adv Rare Dis *7*, 26330040261478640, doi:10.1177/26330040261478640.

Lee, F. S., Lee, C. W., Lee, C. H. et Hunley, V. (2026). **Rare Pyloric Stenosis in Mitochondrial Disease Treated with Hand-Assisted Laparoscopic Pyloromyotomy**. CRSLS *13*, e2026.00033, doi:10.4293/CRSLS.2026.00033.

Li, J.-H. et Zhang, L.-N. (2026). **Molecular functions of deadenylases and their regulatory mechanisms in human diseases: A review**. Int J Biol Macromol *377*, 153618, doi:10.1016/j.ijbiomac.2026.153618.

Li, T., Xu, C., Liu, Z., Liu, Y., Zou, Y., He, Z., Zhang, Y., Sun, M., Xue, H., Li, H. et Fang, F. (2026). **Clinical and modifier gene profiles in reversible infantile respiratory chain deficiency: three Chinese cases report and literature review**. Transl Pediatr *15*, 355, doi:10.21037/tp-2026-0512.

Liang, H., Chen, Z., Huang, S., Wei, H., Xu, J. et Hu, S. (2026). **Domain-Specific Genotype-Phenotype Correlations in DNM1L Disorders: Insights Into Mutation Hotspots and Clinical Severity**. FASEB J *40*, e72087, doi:10.1096/fj.202502759RR.

Lim, A. Z., Moe, A.-M., Stefanetti, R. J. et Ng, Y. S. (2026). **Advances in Primary Mitochondrial Diseases: Diagnosis, Natural History Studies and Clinical Trials**. Genes (Basel) *17*, 850, doi:10.3390/genes17080850.

Lv, J. et Guo, D. (2026). **Progress on Mechanisms of Therapeutic Potential of Oxygen Delivery in Brain Disorders**. Neuroendocrinology 1, doi:10.1159/nen/advag002.

Malagelada, C., Guarino, M., Bonora, E., Lungaro, L., Barbara, G., Stanghellini, V. et De Giorgio, R. (2026). **Clinical presentation, diagnosis and management of chronic intestinal and colonic pseudo-obstruction in neurological diseases**. Auton Neurosci *268*, 103473, doi:10.1016/j.autneu.2026.103473.

Martin-Tissier, A., Bounazou, F., Zablocki, A., Lambert, R., Fargier, G., Roelants, C., Foray, M., Morozzi, G., Liberatore, M., Ventre, E., Young, J., Flaender, M. et Freytag, B. (2026). **MitoLatentProfiler: ROI-constrained deep learning for mitochondrial phenotyping in human myotubes**. SLAS Discov *44*, 100334, doi:10.1016/j.slasd.2026.100334.

Mathot, A. et Maraite, F. (2026). **[Acute anterior ischemic optic neuropathy in the context of mitochondrial disease]**. Rev Med Liege *81*, 536-543.

Medeiros, T. C. et Calabrese, G. (2026). **Metabolic regulation of mitochondrial DNA (mtDNA) homeostasis**. Biochim Biophys Acta Mol Cell Res *1873*, 120220, doi:10.1016/j.bbamcr.2026.120220.

Metitieri, T., Savoca, G., Bartolini, L., Savazzi, S., Lenge, M., Bianchi, A., Procopio, E. et Guerrini, R. (2026). **Case Report of Recovery from Cortical Blindness in a Child with POLG1-Related Disease: A Three-Month Follow-Up**. Dev Neuropsychol *51*, 300-310, doi:10.1080/87565641.2026.2713513.

Misra, S. et Gunn, T. M. (2026). **Beyond Neurodegeneration: White Matter Vacuolation as a Primary Myelin Defect**. Int J Mol Sci *27*, 7066, doi:10.3390/ijms27157066.

Moraes, C. T. (2026). **The power of one: The unexpected benefits of correcting a single tissue in multisystem mitochondrial disease**. Mol Ther *34*, 4355-4357, doi:10.1016/j.ymthe.2026.07.025.

Nakagawa, A., Kanno, C., Watanabe, N., Ohashi, H., Ajihara, S., Murayama, K. et Shimizu, M. (2026). **Immunohistochemical Findings of Organ-Specific ECHS1 Depletion in a Neonate With ECHS1 Deficiency**. Pediatr Int *68*, e70552, doi:10.1111/ped.70552.

Neijmann, S. T., Gedikbasi, A., Tuncer, F. N., Dogan, S. A., Tatonyan, S., Balci, M. C., Bekmez, B., Karaman, V., Gokcay, G. F. et Karakaş, Z. (2026). **Mitochondrial Damage in Hemoglobinopathies: The Role of Cell-Free mtDNA as a Potential Biomarker**. Biomedicines *14*, 2011, doi:10.3390/biomedicines14092011.

Nielsen, S. R., Østergaard, E., Vissing, J. et Frederiksen, A. L. (2026). **[Mitochondrial diseases]**. Ugeskr Laeger *188*, V10250820, doi:10.61409/V10250820.

Norden, P. R., Wedan, R. J., Ellis, A. E., Hart, M. L., Gendjar, M. R., Canfield, M. T., Sheldon, R. D. et Nowinski, S. M. (2026). **Functional partitioning of lipoic acid decouples cellular abundance from mitochondrial utilization**. J Lipid Res *67*, 101126, doi:10.1016/j.jlr.2026.101126.

Okazaki, A., Yatsuka, Y., Fushimi, T., Onuki, T., Aida, Y., Aihara, H., Imasawa, T., Ohtake, A., Murayama, K. et Okazaki, Y. (2026). **Non-invasive urinary heteroplasmy screening outperforms blood testing for certain mitochondrial DNA variants in mitochondrial disease patients**. Mol Genet Metab *148*, 110198, doi:10.1016/j.ymgme.2026.110198.

Plaza-G A, I., Miguez-Amil, S., Hayes, A. M., Ciesielski, G. L., Fernandez-Leiro, R. et Ibarra, B. (2026). **Structural and single-molecule insights into the core human mitochondrial DNA replisome**. Biochem J *483*, 1635-1651, doi:10.1042/BCJ20260373.

Pogoryelova, O., Smeitink, J., Renkema, H., White, R., Barton, F., Lyon, R., Newman, J., Moe, A., Ng, Y. S. et Gorman, G. S. (2026). **Digital Cognitive Testing in Mitochondrial Disease: Validity and Challenges for Clinical Trial Use**. Ann Clin Transl Neurol, doi:10.1002/acn3.70463.

Poon, K.-S., Tan, K. M.-L. et Abdul Murad, N. A. (2026). **Molecular diagnostic platforms for mitochondrial diseases by conventional and long-read sequencing: Missing pieces**. Biomed J *49*, 100992, doi:10.1016/j.bj.2026.100992.

Rajavoor Muniswamy, J. K., Dewey, D. C. et Muthusamy, K. (2026). **Late-onset symmetric cervical and upper thoracic lipomatosis as a presenting manifestation of mitochondrial disorder**. BMJ Case Rep *19*, e272707, doi:10.1136/bcr-2026-272707.

Rebelo, A. P., Lutz, K., Grider, T., Zaidman, C. M., Shy, M. E. et Zuchner, S. (2026). **Biallelic SCO2 Variants Presenting as Motor-Predominant Axonal Neuropathy With Complex IV Deficiency**. J Peripher Nerv Syst *31*, e70150, doi:10.1111/jns.70150.

Remes, C., Mathew, N. D., Miranda, V., Haroon, S., O'Hara, T., Anderson, V. E., Lavorato, M., Keith, K., Xiao, R., Nakamaru-Ogiso, E. et Falk, M. J. (2026). *Dichloroacetate improves animal survival, growth, neuromuscular activity, mitochondrial stress and physiology, and elevated lactate in C. elegans pdha-1 and dld-1 RNAi models of pyruvate dehydrogenase complex deficiency (PDCD)*, doi:10.64898/2026.07.08.737008.

Ruzzenente, B., Becker, P.-H., Afram, E., Gaignard, P., Rötig, A., Nyaga, D. M., Sharpe, C., Sadleir, L. G., Ryder, B. et Metodiev, M. D. (2026). **Functional characterization of a biallelic MIPEP variant associated with global developmental delay, infantile epileptic spasms syndrome, and hypotonia**. Mol Genet Metab Rep *48*, 101335, doi:10.1016/j.ymgmr.2026.101335.

Sabharwal, A., Ali, M. R., Mitra, K. S., Morisue, J., Klein, J., Sarkar, R., Savage, K., Thulung, L. R., Zumbrock, A., Petree, C., Castillo, S. R., Mota, M., Varshney, G. K., Clark, K. J., Nakamuru-Ogiso, E. et Ekker, S. C. (2026). **Systematic Engineering of Loss-of-Function Alleles in the Zebrafish Mitochondrial Proteome.** doi:10.64898/2026.09.14.751483.

Sahibzada, H., Malik, R. et Abu-Amero, K. K. (2026). **Mitochondrial Control of Myelination, Bioenergetics, Oxidative Stress, and the Pathogenesis of Optic Neuropathies**. Int J Mol Sci *27*, 7678, doi:10.3390/ijms27177678.

Saura, P., Badolato, S., Gangdal, A., Beghiah, A. et Kaila, V. R. I. (2026). **Disease-mutations perturb proton transfer reactions in respiratory complex I**. Biochim Biophys Acta Bioenerg *1867*, 149602, doi:10.1016/j.bbabio.2026.149602.

Semmler, L., Büchner, B., Kornblum, C., Deschauer, M., Wortmann, S., La Morgia, C., Servidei, S., Freisinger, P., Mensch, A., Schuelke, M., Prokisch, H., Mancuso, M., Lamperti, C., Klopstock, T., et GENOMIT study group (2026). **Mitochondrial diabetes mellitus: real world insights from the GENOMIT registry-a multinational, longitudinal cohort study**. EBioMedicine *131*, 106458, doi:10.1016/j.ebiom.2026.106458.

Shen, L., Lott, M. T., Mccormick, E. M., Muraresku, C. C., Keller, K., Wallace, D. C., Zolkipli-Cunningham, Z., Rahman, S., Falk, M. J. et Gai, X. (2026). **MSeqDR PMD-VR: An Expert-Curated Virtual Registry of 11,000 Mitochondrial Disease Cases Established Through Literature Mining and Generative AI Augmentation**. Genes (Basel) *17*, 757, doi:10.3390/genes17070757.

Shila, T. A., Ahmad, D., Zhao, J., Tan, H., Wang, B., Zhang, J. et Wang, Y. (2026). **Understanding cardiovascular aging as a disorder of mitochondrial network**. J Cardiovasc Aging *6*, 12, doi:10.20517/jca.2026.07.

Sokolova, V., Buchel, G., Strock, S., Nayak, A. R. et Temiakov, D. (2026). **Molecular and structural basis for replication initiation and strand separation by human mitochondrial DNA polymerase γ**. Nucleic Acids Res *54*, gkag925, doi:10.1093/nar/gkag925.

Solares, I., Alegre, E., Colina, I., Gavira, J. J., Alvarez de Sierra, B., Llorente-Gonzalez, S. et Gonzalez, Á. (2026). **When rare diseases do not appear as a single entity**. Adv Lab Med *7*, 234-237, doi:10.1515/almed-2025-0193.

Starosta, R. T., Friederich, M. W., Preston, G., Walson, L., Yin, J. H., Lang, S., Tadros, H. J., Wang, Y., Mizerik, E., Mirsky, D., Hock, D. H., Stroud, D. A., Sanchez Russo, R., Scaglia, F., Morava, E. et Van Hove, J. L. K. (2026). **Delineation and Phenotypic Expansion of TOP3A-Related Mitochondrial Disease in Childhood**. Am J Med Genet A, doi:10.1002/ajmg.a.70248.

Stocker, R., Mann, J. R. et Carroll, J. (2026). **Pronuclear Transfer and Maternal Spindle Transfer in the Mouse**. Methods Mol Biol *3038*, 477-493, doi:10.1007/978-1-0716-5292-3_25.

Sultan, L. R., Morgan, T. A., McGinn, D. E., Darge, K., Gendler, L., Nguyen, J., Brennan, E., Brother, J. A., Xiao, R., Falk, M. J., Nadkarni, V., Ischiropoulos, H., Adams, J. A. et Zolkipli Cunningham, Z. (2026). **Evaluation of muscle microvascular perfusion in primary mitochondrial disease by contrast-enhanced ultrasound: Feasibility study**. Ther Adv Rare Dis *7*, 26330040261486870, doi:10.1177/26330040261486870.

Svedmyr, S. et Bergqvist, J. (2026). **Daridorexant- Case Report of Possible Side-Effect in Rare Mitochondrial Disorder**. J Sleep Res e70440, doi:10.1111/jsr.70440.

Teng, Y., Luo, C., Xu, Q., Mu, J., Teng, L., Qian, H., Huang, Y., Liu, M., Zhang, L., Park, J. W., Hwang, J. Y., Kong, M., Yan, J., Merchant, M. L. et Zhang, H.-G. (2026). **Plant-derived mitochondria mitigate aging-related neurodegeneration by reprogramming microglial mitochondrial energy metabolism**. Transl Neurodegener *15*, 30, doi:10.1186/s40035-026-00565-1.

Thiebaut de Schotten, M., Liu, C. C., Kelly, C., Bo, K., Wager, T. D., Mosharov, E. V. et Picard, M. (2026). *Individualised mapping of living human brain mitochondria by MRI reveals signatures of bioenergetic defects*, doi:10.21203/rs.3.rs-10117408/v1.

Tobias, M., Dairo, K., Slenkovich, N., Cambier, G. et Tobias, J. D. (2026). **Total Intravenous Anesthesia With Remimazolam and Remifentanil for Intraoperative Care of a Child With Venezuelan Heritage, at Risk for a Mitochondrial Disorder**. J Med Cases *17*, 428-431, doi:10.14740/jmc5358.

Unuakhalu, R., Purcell, A., Jindal, I., Wu, Y., Arnold, M., Dominick, K. C. et Shillington, A. (2026). **The long road to diagnosis: recessive PMPCB deficiency hidden behind a dominant familial VCP defect**. Mol Genet Metab Rep *48*, 101350, doi:10.1016/j.ymgmr.2026.101350.

Valenzuela, R. et Rodríguez-Pérez, A. I. (2026). **Mitochondrial Crossroads in Neurobiology: From Cellular Vulnerability to Therapeutic Opportunity**. Cell Mol Neurobiol *46*, 136, doi:10.1007/s10571-026-01822-7.

Valer, F. B., Spegiorim, G. C., Dos Santos, J. R., Azzolini, A. E. C. S., Oliveira, M. F. et Alberici, L. C. (2026). **Optimized high-resolution respirometry defines the bioenergetic signature of Drosophila melanogaster thoracic muscle**. Biochimie S0300-9084(26)00226-9, doi:10.1016/j.biochi.2026.09.007.

Van Hove, J. L. K., Friederich, M. W., Van Hove, R. A., Lee, J. C., Knight, K. M., Donovan, T. E., Silveira, L., Ganetzky, R. D., Hirano, M., Abdenur, J., Butler, M. G., Cassiman, D., Cohen, B. H., Elsea, S. H., Enns, G. M., Gahl, W. A., Gavrilova, R., Geddes, G. C., Glamuzina, E. E., Goldstein, A., Haas, R. H., Khan, A., Kripps, K. A., Larson, A. A., Lehman, A. N., Lichter-Konecki, U., Mayr, J. A., Morava, E., Peterson, J. T., Rosenfeld, J. A., Saneto, R. P., Scaglia, F., Shelkowitz, E., Simon, M., Smet, J. E. G., Smith, W. E., Soler-Alfonso, C., Tarnopolsky, M., Van Coster, R. N. A., Vanlander, A. V., Vermeersch, P., Vockley, J., Wigby, K., Wolfe, L. A., Wortmann, S. B. et Yang, J. H. (2026). **Comprehensive functional testing in fibroblasts has strong utility to diagnose mitochondrial disease**. EMBO Mol Med *18*, 4153-4172, doi:10.1038/s44321-026-00497-3.

Venter, M., Terburgh, K., Lindeque, J. Z., Ogasawara, E., Janssen, M. C. H., Smeitink, J. A. M., Nakada, K. et Louw, R. (2026). **Cross-species urinary metabolomics identifies 2-hydroxyisovalerate as a candidate biomarker for mtDNA-based disorders**. Metabolomics *22*, 140, doi:10.1007/s11306-026-02518-1.

Wetzel, S., Mann, S. P. et Rosenberger, F. A. (2026). **From Single Cells to Diagnosis: Proteomics Technologies in the Multi-Omics Landscape of Rare and Mitochondrial Diseases**. J Inherit Metab Dis *49*, e70236, doi:10.1002/jimd.70236.

Wong, S. W., Tomlin, F. et Stojanovic, J. (2026). **Immunosuppression in children with primary mitochondrial diseases after kidney transplantation: insight from case series of RMND1-related disease**. Pediatr Nephrol, doi:10.1007/s00467-026-07527-9.

Xu, Y., Behrouz, B., Lee, A., Xin, G. et Sun, N. (2026). **Deubiquitinases in mitophagy: therapeutic control of mitochondrial quality**. Trends Pharmacol Sci *47*, 1099-1115, doi:10.1016/j.tips.2026.08.009.

Yan, C., Zhang, S., Zhang, P., Zhang, J., Liu, Yang, Zhou, H., Jiang, H., Zhang, Z., Guo, J., Zhang, W., Liang, F., Zou, Z., Chen, J., Chen, W., Lu, X., Yu, L., Xie, W., Pi, C., Zhao, H., Liu, Yusha, Ma, J., Gao, S., Yu, S. et Wu, S. (2026). **Mitochondrial migraine: A multicenter study based on mitochondrial diseases presenting as encephalopathy and/or myopathy**. Headache, doi:10.1111/head.70225.

Yao, S.-Y., Wang, M., Wei, F.-Y. et Zhou, X.-L. (2026). **Modification and aminoacylation of human mitochondrial tRNAs**. Trends Biochem Sci *51*, 937-954, doi:10.1016/j.tibs.2026.06.009.

Yatsuga, S. (2026). **Severe mitochondrial cardiomyopathy with m.3303C > T variant in the mitochondrial tRNALeu(UUR) gene: A study of large family analysis**. Mol Genet Metab Rep *48*, 101348, doi:10.1016/j.ymgmr.2026.101348.

Yi, Z., Ni, X., Guo, M., Shao, H., Chen, X. et Zhang, F. (2026). **Global trends and hotspots in diabetes and hearing loss: a 20-year systematic bibliometric study**. Front Med (Lausanne) *13*, 1867924, doi:10.3389/fmed.2026.1867924.

Yildiz, A., Yildiz, M. T. et Onal, H. (2026). **Diagnostic utility of FGF-21 and GDF-15 for differentiating primary mitochondrial diseases from lysosomal storage disorders associated with secondary mitochondrial dysfunction: a machine learning-based multimetabolite approach**. Mol Genet Metab *149*, 110246, doi:10.1016/j.ymgme.2026.110246.

Yıldız, Y., Çetin, F. S., İyigün, İ., Unal, S., Şimşek Kiper, P. Ö., Deren, Ö. et Haliloğlu, G. (2026). **Child Neurology: Arthrogryposis and Antenatal-Onset Hyperkinetic Movements in a Newborn**. Neurology *107*, e218361, doi:10.1212/WNL.0000000000218361.

Yoga Ratnam, K. K. et Yap, J. F. (2026). **The long road to a rare diagnosis: A Malaysian case of childhood-onset progressive myoclonus, ataxia, and retinal dystrophy with biopsy features suggestive of mitochondrial dysfunction**. J Int Med Res *54*, 3000605261467202, doi:10.1177/03000605261467202.

Yonar, H., Beşoluk, F. Ç. et Parlak, T. M. (2026). **A Mechanism-Centered Text-Mining Landscape of Mitochondrial Bioenergetics and Signaling in Disease Research**. Int J Mol Sci *27*, 6577, doi:10.3390/ijms27156577.

Yuan, E., Zhang, N., He, H., Zhang, T., Chen, E., Zhang, Q. et Ji, D. (2026). **Decoding the Genetic and Phenotypic Spectrum of MT-TI Mitochondrial Diseases**. Ann Hum Genet, doi:10.1111/ahg.70056.

Yue, Y., Zhao, F. et Chen, Q. (2026). **COQ2-Associated Primary Coenzyme Q10 Deficiency Presenting With Proteinuria: A Case Report and Literature Review**. Mol Genet Genomic Med *14*, e70221, doi:10.1002/mgg3.70221.

Zhang, H., Wang, C., Zhang, Y., Xiang, Y., Fan, S., Meng, L., Qin, J., Guo, J., He, Z., Deng, Z., Zhao, L., Lei, L., Hou, S., Zeng, M., Wang, Q. et Ren, C. (2026). **Genetic ablation of Sfxn5 induces mitochondrial dysfunction and precipitates lethal metabolic crisis in mice**. iScience *29*, 116468, doi:10.1016/j.isci.2026.116468.

Zhang, Y., Xu, J., Chan, W., Chen, H., Wu, J., Guo, Y., Yao, R.-E. et Fu, L. (2026). **TOP3A pathogenic variants presenting as dilated cardiomyopathy and heart failure in three pediatric cases**. BMC Pediatr, doi:10.1186/s12887-026-07361-w.